1
|
Eriksson M, Hayat R, Kinsella E, Lewis K, White DCS, Boyd J, Bullen A, Maclean M, Stoddart A, Phair S, Evans H, Noakes J, Alexander D, Keerie C, Linsley C, Milne G, Norrie J, Farrar N, Realpe AX, Donovan JL, Bunch J, Douthwaite K, Temple S, Hogg J, Scott D, Spallone P, Stuart I, Wardlaw JM, Palmer J, Sakka E, Mukerji N, Cirstea E, Davies S, Giannakaki V, Kadhim A, Kennion O, Islam M, Ferguson L, Prasad M, Bacon A, Richards E, Howe J, Kamara C, Gardner J, Roman M, Sikaonga M, Cahill J, Rossdeutsch A, Cahill V, Hamina I, Chaudhari K, Danciut M, Clarkson E, Bjornson A, Bulters D, Digpal R, Ruiz W, Taylor M, Anyog D, Tluchowska K, Nolasco J, Brooks D, Angelopoulou K, Welch B, Broomes N, Fouyas I, MacRaild A, Kaliaperumal C, Teasdale J, Coakley M, Brennan P, Sokol D, Wiggins A, MacDonald M, Risbridger S, Bhatt P, Irvine J, Majeed S, Williams S, Reid J, Walch A, Muir F, van Beijnum J, Leach P, Hughes T, Makwana M, Hamandi K, McAleer D, Gunning B, Walsh D, Wroe Wright O, Patel S, Gurusinghe N, Raza-Knight S, Cromie TL, Brown A, Raj S, Pennington R, Campbell C, Patel S, Colombo F, Teo M, Wildman J, Smith K, Goff E, Stephens D, Borislavova B, Worner R, Buddha S, Clatworthy P, Edwards R, Clayton E, Coy K, Tucker L, Dymond S, Mallick A, Hodnett R, Spickett-Jones F, Grover P, Banaras A, Tshuma S, Muirhead W, Scott Hill C, Shah R, Doke T, Hall R, Coskuner S, Aslett L, Vindlacheruvu R, Ghosh A, Fitzpatrick T, Harris L, Hayton T, Whitehouse A, McDarby A, Hancox R, Auyeung CK, Nair R, Thomas R, McLachlan H, Kountourgioti A, Orjales G, Kruczynski J, Hunter S, Bohnacker N, Marimon R, Parker L, Raha O, Sharma P, Uff C, Boyapati G, Papadopoulos M, Kearney S, Visagan R, Bosetta E, Asif H, Helmy A, Chapas L, Tarantino S, Caldwell K, Guilfoyle M, Agarwal S, Brown D, Holland S, Tajsic T, Fletcher C, Sebyatki A, Ushewokunze S, Ali S, Preston J, Chambers C, Patel M, Holsgrove D, McLaughlan D, Marsden T, Colombo F, Cawley K, Raffalli H, Lee S, Israni A, Dore R, Anderson T, Hennigan D, Mayor S, Glover S, Chavredakis E, Brown D, Sokratous G, Williamson J, Stoneley C, Brodbelt A, Farah JO, Illingworth S, Konteas AB, Davies D, Owen C, Kerr L, Hall P, Al-Shahi Salman R, Forsyth L, Lewis SC, Loan JJM, Neilson AR, Stephen J, Kitchen N, Harkness KA, Hutchinson PJA, Mallucci C, Wade J, White PM. Medical management and surgery versus medical management alone for symptomatic cerebral cavernous malformation (CARE): a feasibility study and randomised, open, pragmatic, pilot phase trial. Lancet Neurol 2024; 23:565-576. [PMID: 38643777 DOI: 10.1016/s1474-4422(24)00096-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/29/2024] [Revised: 03/01/2024] [Accepted: 03/04/2024] [Indexed: 04/23/2024]
Abstract
BACKGROUND The highest priority uncertainty for people with symptomatic cerebral cavernous malformation is whether to have medical management and surgery or medical management alone. We conducted a pilot phase randomised controlled trial to assess the feasibility of addressing this uncertainty in a definitive trial. METHODS The CARE pilot trial was a prospective, randomised, open-label, assessor-blinded, parallel-group trial at neuroscience centres in the UK and Ireland. We aimed to recruit 60 people of any age, sex, and ethnicity who had mental capacity, were resident in the UK or Ireland, and had a symptomatic cerebral cavernous malformation. Computerised, web-based randomisation assigned participants (1:1) to medical management and surgery (neurosurgical resection or stereotactic radiosurgery) or medical management alone, stratified by the neurosurgeon's and participant's consensus about the intended type of surgery before randomisation. Assignment was open to investigators, participants, and carers, but not clinical outcome event adjudicators. Feasibility outcomes included site engagement, recruitment, choice of surgical management, retention, adherence, data quality, clinical outcome event rate, and protocol implementation. The primary clinical outcome was symptomatic intracranial haemorrhage or new persistent or progressive non-haemorrhagic focal neurological deficit due to cerebral cavernous malformation or surgery during at least 6 months of follow-up. We analysed data from all randomly assigned participants according to assigned management. This trial is registered with ISRCTN (ISRCTN41647111) and has been completed. FINDINGS Between Sept 27, 2021, and April 28, 2023, 28 (70%) of 40 sites took part, at which investigators screened 511 patients, of whom 322 (63%) were eligible, 202 were approached for recruitment, and 96 had collective uncertainty with their neurosurgeon about whether to have surgery for a symptomatic cerebral cavernous malformation. 72 (22%) of 322 eligible patients were randomly assigned (mean recruitment rate 0·2 [SD 0·25] participants per site per month) at a median of 287 (IQR 67-591) days since the most recent symptomatic presentation. Participants' median age was 50·6 (IQR 38·6-59·2) years, 68 (94%) of 72 participants were adults, 41 (57%) were female, 66 (92%) were White, 56 (78%) had a previous intracranial haemorrhage, and 28 (39%) had a previous epileptic seizure. The intended type of surgery before randomisation was neurosurgical resection for 19 (26%) of 72, stereotactic radiosurgery for 44 (61%), and no preference for nine (13%). Baseline clinical and imaging data were complete for all participants. 36 participants were randomly assigned to medical management and surgery (12 to neurosurgical resection and 24 to stereotactic radiosurgery) and 36 to medical management alone. Three (4%) of 72 participants withdrew, one was lost to follow-up, and one declined face-to-face follow-up, leaving 67 (93%) retained at 6-months' clinical follow-up. 61 (91%) of 67 participants with follow-up adhered to the assigned management strategy. The primary clinical outcome occurred in two (6%) of 33 participants randomly assigned to medical management and surgery (8·0%, 95% CI 2·0-32·1 per year) and in two (6%) of 34 participants randomly assigned to medical management alone (7·5%, 1·9-30·1 per year). Investigators reported no deaths, no serious adverse events, one protocol violation, and 61 protocol deviations. INTERPRETATION This pilot phase trial exceeded its recruitment target, but a definitive trial will require extensive international engagement. FUNDING National Institute for Health and Care Research.
Collapse
|
2
|
Persson K, Boeg Thomsen D, Fyrberg Å, Castor C, Aasved Hjort M, Andreozzi B, Grillner P, Kjær Grønbæk J, Jakus J, Juhler M, Mallucci C, Mathiasen R, Molinari E, Pizer B, Sehested A, Troks-Berzinskiene A, van Baarsen K, Tiberg I. Preoperative word-finding difficulties in children with posterior fossa tumours: a European cross-sectional study. Childs Nerv Syst 2024; 40:87-97. [PMID: 37682305 PMCID: PMC10761395 DOI: 10.1007/s00381-023-06119-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/28/2023] [Accepted: 08/04/2023] [Indexed: 09/09/2023]
Abstract
PURPOSE Posterior fossa tumour surgery in children entails a high risk for severe speech and language impairments, but few studies have investigated the effect of the tumour on language prior to surgery. The current crosslinguistic study addresses this gap. We investigated the prevalence of preoperative word-finding difficulties, examined associations with medical and demographic characteristics, and analysed lexical errors. METHODS We included 148 children aged 5-17 years with a posterior fossa tumour. Word-finding ability was assessed by means of a picture-naming test, Wordrace, and difficulties in accuracy and speed were identified by cut-off values. A norm-based subanalysis evaluated performance in a Swedish subsample. We compared the demographic and medical characteristics of children with slow, inaccurate, or combined slow and inaccurate word finding to the characteristics of children without word-finding difficulties and conducted a lexical error analysis. RESULTS Thirty-seven percent (n = 55) presented with slow word finding, 24% (n = 35) with inaccurate word finding, and 16% (n = 23) with both slow and inaccurate word finding. Children with posterior fossa tumours were twice as slow as children in the norming sample. Right-hemisphere and brainstem location posed a higher risk for preoperative word-finding difficulties, relative to left-hemisphere location, and difficulties were more prevalent in boys than in girls. The most frequent errors were lack of response and semantically related sideordinated words. CONCLUSION Word-finding difficulties are frequent in children with posterior fossa tumours, especially in boys and in children with right-hemisphere and brainstem tumours. Errors resemble those observed in typical development and children with word-finding difficulties.
Collapse
Affiliation(s)
- K Persson
- Department of Health Sciences, Lund University, Box 117, 221 00, Lund, Sweden.
| | - D Boeg Thomsen
- Department of Nordic Studies and Linguistics, University of Copenhagen, Emil Holms Kanal 2, 2300, Copenhagen, Denmark
- Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - Å Fyrberg
- Department of Speech and Language Pathology, University of Gothenburg, Medicinaregatan 11, 405 30, Gothenburg, Sweden
| | - C Castor
- Department of Health Sciences, Lund University, Box 117, 221 00, Lund, Sweden
| | - M Aasved Hjort
- Department of Pediatric Hematology and Oncology, St Olavs Hospital, Postboks 3250 Torgarden, 7006, Trondheim, Norway
| | - B Andreozzi
- Department of Hematology/Oncology, Cell and Gene Therapy, Bambino Gesù Children's Hospital, IRCCS, Rome, Italy
| | - P Grillner
- Pediatric Oncology Unit, Astrid Lindgren's Children's Hospital, Karolinskavägen 6, 171 76, Stockholm, Sweden
| | - J Kjær Grønbæk
- Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - J Jakus
- WOW Speech Studio, Üllői út 189, Budapest, 1091, Hungary
| | - M Juhler
- Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
- Department of Neurosurgery, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark
| | - C Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, E. Prescot Road, Liverpool, L14 5AB, UK
| | - R Mathiasen
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - E Molinari
- University of Edinburgh, Old College, South Bridge, Edinburgh, EH8 9YL, UK
- Department of Neurology, The Queen Elizabeth University Hospital, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK
| | - B Pizer
- University of Liverpool, Brownlow Hill, Liverpool, L69 3BX, UK
| | - A Sehested
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - A Troks-Berzinskiene
- Department of Pediatrics, Lithuanian, University of Health Science, Mickeviciaus 9, 44307, Kaunas, Lithuania
| | - K van Baarsen
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands
| | - I Tiberg
- Department of Health Sciences, Lund University, Box 117, 221 00, Lund, Sweden
| |
Collapse
|
3
|
Sleurs C, Fletcher P, Mallucci C, Avula S, Ajithkumar T. Neurocognitive Dysfunction After Treatment for Pediatric Brain Tumors: Subtype-Specific Findings and Proposal for Brain Network-Informed Evaluations. Neurosci Bull 2023; 39:1873-1886. [PMID: 37615933 PMCID: PMC10661593 DOI: 10.1007/s12264-023-01096-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/26/2022] [Accepted: 06/05/2023] [Indexed: 08/25/2023] Open
Abstract
The increasing number of long-term survivors of pediatric brain tumors requires us to incorporate the most recent knowledge derived from cognitive neuroscience into their oncological treatment. As the lesion itself, as well as each treatment, can cause specific neural damage, the long-term neurocognitive outcomes are highly complex and challenging to assess. The number of neurocognitive studies in this population grows exponentially worldwide, motivating modern neuroscience to provide guidance in follow-up before, during and after treatment. In this review, we provide an overview of structural and functional brain connectomes and their role in the neuropsychological outcomes of specific brain tumor types. Based on this information, we propose a theoretical neuroscientific framework to apply appropriate neuropsychological and imaging follow-up for future clinical care and rehabilitation trials.
Collapse
Affiliation(s)
- Charlotte Sleurs
- Department of Cognitive Neuropsychology, Tilburg University, 5037 AB, Tilburg, The Netherlands.
- Department of Oncology, KU Leuven, 3000, Leuven, Belgium.
| | - Paul Fletcher
- Department of Psychiatry, University of Cambridge, Addenbrookes Hospital, Cambridge, CB2 0QQ, UK
- Wellcome Trust MRC Institute of Metabolic Science, University of Cambridge, Cambridge Biomedical Campus, Cambridge, CB2 0QQ, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L14 5AB, UK
| | - Shivaram Avula
- Department of Radiology, Alder Hey Children's NHS Foundation Trust, Liverpool, L14 5AB, UK
| | - Thankamma Ajithkumar
- Department of Oncology, Cambridge University Hospital NHS Trust, Cambridge, CB2 0QQ, UK
| |
Collapse
|
4
|
Apostolopoulou K, Setia V, Pettorini B, Parks C, Ellenbogen J, Dawes W, Mallucci C, Mehta B, Sinha A. Secure windows for child safety: a retrospective study of window falls in children, aiming to raise prevention awareness. Childs Nerv Syst 2023; 39:3195-3205. [PMID: 37093265 PMCID: PMC10124675 DOI: 10.1007/s00381-023-05964-7] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/13/2022] [Accepted: 04/16/2023] [Indexed: 04/25/2023]
Abstract
PURPOSE The aim of the study is to enhance understanding, raise awareness and inform prevention programmes regarding potential factors that lead to severe paediatric injuries caused by unintentional falls from windows. METHODS This is a retrospective review from a major Trauma Centre, covering the majority of North West England and North Wales and included children under the age of 16 that had sustained falls from windows and were hospitalised between April 2015 and June 2020. RESULTS Overall, 825 patients' records have been reviewed, 39% of which exhibited neurosurgical injuries (322 admissions). The most common cause of injury was falls (42%), out of which 19% was identified as falls from windows which was eventually the core focus of this review (25 patients). The records showed that 72% of the falls were not witnessed by another individual, suggesting that children were being left unattended. Average GCS recorded at presentation was 11.2 and 56% of cases were identified as severe major traumas. With a mean stay of 2.2 days in ICU, 1.6 days in HDU and 6 days in the neurosurgical clinic, average treatment costs per patient were £4,493, £651 and £4,156 respectively. Finally, 52% of patients were identified to require long-term physiotherapy/occupational therapy due to permanent disabilities, 20% long-term antiepileptic treatment for seizures and 44% long-term psychological services input. CONCLUSION This study presents our experience at a major tertiary trauma centre in the UK over a 5-year period, from a paediatric neurosurgical injuries perspective due to fall from windows. We aim to raise awareness and highlight the importance of establishing prevention programmes which would hopefully decrease the incidence of paediatric window falls.
Collapse
Affiliation(s)
| | - Vikrant Setia
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Benedetta Pettorini
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Chris Parks
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Jonathan Ellenbogen
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - William Dawes
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Bimal Mehta
- A&E Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Ajay Sinha
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
5
|
Gan HW, Morillon P, Albanese A, Aquilina K, Chandler C, Chang YC, Drimtzias E, Farndon S, Jacques TS, Korbonits M, Kuczynski A, Limond J, Robinson L, Simmons I, Thomas N, Thomas S, Thorp N, Vargha-Khadem F, Warren D, Zebian B, Mallucci C, Spoudeas HA. National UK guidelines for the management of paediatric craniopharyngioma. Lancet Diabetes Endocrinol 2023; 11:694-706. [PMID: 37549682 DOI: 10.1016/s2213-8587(23)00162-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/20/2023] [Revised: 05/25/2023] [Accepted: 06/01/2023] [Indexed: 08/09/2023]
Abstract
Although rare, craniopharyngiomas constitute up to 80% of tumours in the hypothalamic-pituitary region in childhood. Despite being benign, the close proximity of these tumours to the visual pathways, hypothalamus, and pituitary gland means that both treatment of the tumour and the tumour itself can cause pronounced long-term neuroendocrine morbidity against a background of high overall survival. To date, the optimal management strategy for these tumours remains undefined, with practice varying between centres. In light of these discrepancies, as part of a national endeavour to create evidence-based and consensus-based guidance for the management of rare paediatric endocrine tumours in the UK, we aimed to develop guidelines, which are presented in this Review. These guidelines were developed under the auspices of the UK Children's Cancer and Leukaemia Group and the British Society for Paediatric Endocrinology and Diabetes, with the oversight and endorsement of the Royal College of Paediatrics and Child Health using Appraisal of Guidelines for Research & Evaluation II methodology to standardise care for children and young people with craniopharyngiomas.
Collapse
Affiliation(s)
- Hoong-Wei Gan
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; University College London Great Ormond Street Institute of Child Health, London, UK.
| | - Paul Morillon
- King's College Hospital NHS Foundation Trust, London, UK
| | - Assunta Albanese
- St George's University Hospitals NHS Foundation Trust, London, UK
| | - Kristian Aquilina
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Chris Chandler
- King's College Hospital NHS Foundation Trust, London, UK
| | - Yen-Ching Chang
- University College London Hospitals NHS Foundation Trust, London, UK
| | - Evangelos Drimtzias
- St James' University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Sarah Farndon
- Bristol Royal Hospital for Children, University Hospitals Bristol NHS Foundation Trust, Bristol, UK
| | - Thomas S Jacques
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; University College London Great Ormond Street Institute of Child Health, London, UK
| | - Márta Korbonits
- William Harvey Research Institute, Barts and the London School of Medicine and Dentistry, Queen Mary University of London, London, UK
| | - Adam Kuczynski
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Jennifer Limond
- Department of Psychology, College of Life and Environmental Sciences, University of Exeter, Exeter, UK
| | - Louise Robinson
- Royal Manchester Children's Hospital, Manchester University NHS Foundation Trust, Manchester, UK
| | - Ian Simmons
- St James' University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Nick Thomas
- King's College Hospital NHS Foundation Trust, London, UK
| | - Sophie Thomas
- Nottingham Children's Hospital, Queens Medical Centre, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Nicola Thorp
- The Clatterbridge Cancer Centre NHS Foundation Trust, Clatterbridge Road, Bebington, UK
| | - Faraneh Vargha-Khadem
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK; University College London Great Ormond Street Institute of Child Health, London, UK
| | - Daniel Warren
- St James' University Hospital, Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Bassel Zebian
- King's College Hospital NHS Foundation Trust, London, UK
| | - Conor Mallucci
- Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | | |
Collapse
|
6
|
Aziz N, Duddy JC, Saeed D, Hennigan D, Israni A, Puthuran M, Chandran A, Mallucci C. Multi-modality treatment approach for paediatric AVMs with quality-of-life outcome measures. Childs Nerv Syst 2023; 39:2439-2447. [PMID: 37198451 DOI: 10.1007/s00381-023-05954-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/25/2023] [Accepted: 04/05/2023] [Indexed: 05/19/2023]
Abstract
PURPOSE Despite the potentially devastating and permanently disabling effects of paediatric arteriovenous malformations (pAVMs), there is a paucity of studies reporting long-term quality-of-life (QoL) outcomes in AVM patients. We aim to evaluate the management strategies for paediatric intracranial pAVMs in the UK and long-term QoL outcomes using a validated paediatric quality-of-life outcome measure. METHODS In this single-centre case-series, we retrospectively reviewed a prospectively maintained database of all paediatric patients (i.e. 0-18 years old) with intracranial AVMs, who were managed at Alder Hey Children's Hospital from July 2007 to December 2021. We also collected the PedsQL 4.0 score for these patients as a measure of QoL. RESULTS Fifty-two AVMs were included in our analysis. Forty (80%) were ruptured, 8 (16%) required emergency intervention, 17 (35%) required elective surgery, 15 (30%) underwent endovascular embolisation, and 15 (30%) patients underwent stereotactic radiosurgery. There was an 88% overall obliteration rate. Two (4%) pAVMs rebled, and there were no mortalities. Overall, the mean time from diagnosis to definitive treatment was 144 days (median 119; range 0-586). QoL outcomes were collected for 26 (51%) patients. Ruptured pAVM presentation was associated with worse QoL (p = 0.0008). Location impacted psychosocial scores significantly (71.4, 56.9, and 46.6 for right supratentorial, left supratentorial, and infratentorial, respectively; p = 0.04). CONCLUSION This study shows a staged multi-modality treatment approach to pAVMs is safe and effective, with superior obliteration rates with surgery alone. QoL scores are impacted by AVM presentation and location regardless of treatment modality.
Collapse
Affiliation(s)
- Natasha Aziz
- School of Medicine, University of Liverpool, Liverpool, UK.
| | - John C Duddy
- Department of Neurosurgery, AlderHey Children's NHS Foundation Trust, Liverpool, UK
| | - Danial Saeed
- Department of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Dawn Hennigan
- Department of Neurosurgery, AlderHey Children's NHS Foundation Trust, Liverpool, UK
| | - Anil Israni
- Department of Neurology, AlderHey Children's NHS Foundation Trust, Liverpool, UK
| | - Mani Puthuran
- Department of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Arun Chandran
- Department of Neuroradiology, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, AlderHey Children's NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
7
|
Loan JJM, Bacon A, van Beijnum J, Bhatt P, Bjornson A, Broomes N, Bullen A, Bulters D, Cahill J, Chavredakis E, Colombo F, Danciut M, Digpal R, Edwards RJ, Ferguson L, Forsyth L, Fouyas I, Ganesan V, Grover P, Gurusinghe N, Hall PS, Harkness K, Harris LS, Hayton T, Helmy A, Holsgrove D, Hutchinson PJ, Israni A, Kinsella E, Lewis S, Majeed S, Mallucci C, Mukerji N, Nair R, Neilson AR, Papadopoulos MC, Radatz M, Rossdeutsch A, Raza-Knight S, Stephen J, Stoddart A, Teo M, Turner C, Wade J, Walsh D, White D, White P, Wildman J, Wroe Wright O, Uff C, Ushewokunze S, Vindlacheruvu R, Kitchen N, Al-Shahi Salman R. Feasibility of comparing medical management and surgery (with neurosurgery or stereotactic radiosurgery) with medical management alone in people with symptomatic brain cavernoma - protocol for the Cavernomas: A Randomised Effectiveness (CARE) pilot trial. BMJ Open 2023; 13:e075187. [PMID: 37558454 PMCID: PMC10414059 DOI: 10.1136/bmjopen-2023-075187] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/28/2023] [Accepted: 06/29/2023] [Indexed: 08/11/2023] Open
Abstract
INTRODUCTION The top research priority for cavernoma, identified by a James Lind Alliance Priority setting partnership was 'Does treatment (with neurosurgery or stereotactic radiosurgery) or no treatment improve outcome for people diagnosed with a cavernoma?' This pilot randomised controlled trial (RCT) aims to determine the feasibility of answering this question in a main phase RCT. METHODS AND ANALYSIS We will perform a pilot phase, parallel group, pragmatic RCT involving approximately 60 children or adults with mental capacity, resident in the UK or Ireland, with an unresected symptomatic brain cavernoma. Participants will be randomised by web-based randomisation 1:1 to treatment with medical management and with surgery (neurosurgery or stereotactic radiosurgery) versus medical management alone, stratified by prerandomisation preference for type of surgery. In addition to 13 feasibility outcomes, the primary clinical outcome is symptomatic intracranial haemorrhage or new persistent/progressive focal neurological deficit measured at 6 monthly intervals. An integrated QuinteT Recruitment Intervention (QRI) evaluates screening logs, audio recordings of recruitment discussions, and interviews with recruiters and patients/parents/carers to identify and address barriers to participation. A Patient Advisory Group has codesigned the study and will oversee its progress. ETHICS AND DISSEMINATION This study was approved by the Yorkshire and The Humber-Leeds East Research Ethics Committee (21/YH/0046). We will submit manuscripts to peer-reviewed journals, describing the findings of the QRI and the Cavernomas: A Randomised Evaluation (CARE) pilot trial. We will present at national specialty meetings. We will disseminate a plain English summary of the findings of the CARE pilot trial to participants and public audiences with input from, and acknowledgement of, the Patient Advisory Group. TRIAL REGISTRATION NUMBER ISRCTN41647111.
Collapse
Affiliation(s)
- James J M Loan
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
- Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh, UK
| | | | | | | | | | - Nicole Broomes
- University Hospital Southampton NHS Foundation Trust Wessex Neurological Centre, Southampton, UK
| | - Alistair Bullen
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | - Diederik Bulters
- University Hospital Southampton NHS Foundation Trust Wessex Neurological Centre, Southampton, UK
| | - Julian Cahill
- National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Sheffield, UK
| | | | | | | | - Ronneil Digpal
- University Hospital Southampton NHS Foundation Trust Wessex Neurological Centre, Southampton, UK
| | | | | | - Laura Forsyth
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | - Ioannis Fouyas
- Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh, UK
| | - Vijeya Ganesan
- Developmental Neurosciences Department, Great Ormond Street Hospital for Children, London, UK
| | - Patrick Grover
- The National Hospital for Neurology & Neurosurgery, London, UK
| | | | - Peter S Hall
- Institute of Genetics and Cancer, University of Edinburgh, Edinburgh, UK
| | | | | | - Tom Hayton
- Queen Elizabeth Hospital, Birmingham, UK
| | - Adel Helmy
- Clinical Neurosciences, University of Cambridge, Cambridge, UK
- Addenbrooke's Hospital, Cambridge, UK
| | - Daniel Holsgrove
- Centre for Clinical Neurosciences, Salford Royal Hospital Manchester, Salford, UK
| | - Peter J Hutchinson
- Clinical Neurosciences, University of Cambridge, Cambridge, UK
- Addenbrooke's Hospital, Cambridge, UK
| | - Anil Israni
- Alder Hey Children's Hospital, Liverpool, UK
| | - Elaine Kinsella
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | - Steff Lewis
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | | | | | | | | | - Aileen R Neilson
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | | | - Matthias Radatz
- National Centre for Stereotactic Radiosurgery, Royal Hallamshire Hospital, Sheffield, UK
| | | | | | - Jacqueline Stephen
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | - Andrew Stoddart
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| | - Mario Teo
- Department of Neurosurgery, Southmead Hospital, Bristol, UK
| | - Carole Turner
- Clinical Neurosciences, University of Cambridge, Cambridge, UK
- Addenbrooke's Hospital, Cambridge, UK
| | - Julia Wade
- Population Health Science, Bristol Medical School, University of Bristol, Bristol, UK
| | - Daniel Walsh
- King's College Hospital, London, UK
- Institute of Psychiatry Psychology & Neuroscience, King's College London, London, UK
| | | | - Phil White
- Newcastle University Translational and Clinical Research Institute, Newcastle upon Tyne, UK
| | - Jack Wildman
- Department of Neurosurgery, Southmead Hospital, Bristol, UK
| | | | | | | | | | - Neil Kitchen
- The National Hospital for Neurology & Neurosurgery, London, UK
| | - Rustam Al-Shahi Salman
- Centre for Clinical Brain Sciences, The University of Edinburgh, Edinburgh, UK
- Department of Clinical Neurosciences, Royal Infirmary of Edinburgh, Edinburgh, UK
- Edinburgh Clinical Trials Unit, The University of Edinburgh Usher Institute of Population Health Sciences and Informatics, Edinburgh, UK
| |
Collapse
|
8
|
Hall BJ, Duddy JC, Apostolopoulou K, David R, Kurzbuch A, Nadkarni A, Trichinopoly Krishna S, Cooper B, Gouldbourne H, Hennigan D, Dawes W, Ellenbogen J, Parks C, Pettorini B, Sinha A, Mallucci C. Intracranial Empyemas in the COVID-19 Era: A New Phenomenon? A Paediatric Case Series and Review of the Literature. Pediatr Neurosurg 2023; 58:215-222. [PMID: 37393893 PMCID: PMC10614506 DOI: 10.1159/000531753] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Accepted: 06/01/2023] [Indexed: 07/04/2023]
Abstract
INTRODUCTION We present the largest series of paediatric intracranial empyemas occurring after COVID-19 infection to date, and discuss the potential implications of the pandemic on this neurosurgical pathology. METHODS Patients admitted to our centre between January 2016 and December 2021 with a confirmed radiological diagnosis of intracranial empyema were retrospectively reviewed, excluding non-otorhinological source cases. Patients were grouped according to onset before or after onset of the COVID-19 pandemic and COVID-19 status. A literature review of all post-COVID-19 intracranial empyemas was performed. SPSS v27 was used for statistical analysis. RESULTS Sixteen patients were diagnosed with intracranial empyema: n = 5 prior to 2020 and n = 11 after, resulting in an average annual incidence of 0.3% prior to onset of the pandemic and 1.2% thereafter. Of those diagnosed since the pandemic, 4 (25%) were confirmed to have COVID-19 on recent PCR test. Time from COVID-19 infection until empyema diagnosis ranged from 15 days to 8 weeks. Mean age for post-COVID-19 cases was 8.5 years (range: 7-10 years) compared to 11 years in non-COVID cases (range: 3-14 years). Streptococcus intermedius was grown in all cases of post-COVID-19 empyema, and 3 of 4 (75%) post-COVID-19 cases developed cerebral sinus thromboses, compared to 3 of 12 (25%) non-COVID-19 cases. All cases were discharged home with no residual deficit. CONCLUSION Our post-COVID-19 intracranial empyema series demonstrates a greater proportion of cerebral sinus thromboses than non-COVID-19 cases, potentially reflecting the thrombogenic effects of COVID-19. Incidence of intracranial empyema at our centre has increased since the start of the pandemic, causes of which require further investigation and multicentre collaboration.
Collapse
Affiliation(s)
- Benjamin J Hall
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - John C Duddy
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Katerina Apostolopoulou
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Raenette David
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Arthur Kurzbuch
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Abhishek Nadkarni
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | | | - Ben Cooper
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Hayley Gouldbourne
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Dawn Hennigan
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - William Dawes
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Jonathan Ellenbogen
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Christopher Parks
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Benedetta Pettorini
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Ajay Sinha
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
9
|
Wright SH, Blumenow W, Kumar R, Mallucci C, Felton A, McMahon S, Hennigan D, Avula S, Pizer B. Prevalence of dysphagia following posterior fossa tumour resection in children: the Alder Hey experience. Childs Nerv Syst 2023; 39:609-616. [PMID: 36512048 DOI: 10.1007/s00381-022-05774-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/06/2022] [Accepted: 11/23/2022] [Indexed: 12/15/2022]
Abstract
BACKGROUND Surgery for posterior fossa tumours (PFTs) in children is associated with bulbar palsy and swallowing difficulties although this risk is not well defined in the literature and issues contributing to dysphagia following surgery are not fully understood. AIMS This study aims to study the eating, drinking and swallowing function of children following PFT resection in a specialist paediatric neurosurgery centre. This included the frequency and duration of dysphagia, the risk of aspiration and the link between tumour type and dysphagia. MATERIALS AND METHODS This is a retrospective review of children undergoing surgery for PFT between 2014 and 2019. Information was obtained from the patients' hospital and speech and language therapy (SLT) notes, oncology database and clinical letters. The International Dysphagia Diet Standardisation Initiative (IDDSI) Framework was used to describe food and fluid modifications. RESULTS Seventy children had surgery to resect a posterior fossa tumour at Alder Hey from 2014 to 2019. Thirty-one children were included in the study following referral to SLT. Videofluoroscopy (VF) was undertaken at our institution in 68% (21/31) of cases. Fifty-two percent (11/21) of children aspirated or were considered at risk, and 55% (6/11) of those who aspirated showed silent aspiration. After 3 months, 43% (13/30) still required modified food and/or fluid textures, with this proportion reducing as time progressed. By tumour type, VF was performed in 5/7 medulloblastoma patients with 3/5 showing aspiration and 3/3 silently aspirating; in 8/9 patients with ependymoma with 4/8 patients aspirating with 2/4 showing silent aspiration; and 6/12 glioma patients with 4/6 aspirating with 1/4 showing silent aspiration. CONCLUSION Swallowing difficulties, including silent aspiration, are an important complication of PFT resection. A proportion of children will need ongoing food and/or fluid modification. Further study into dysphagia following PFT resection is indicated.
Collapse
Affiliation(s)
- Samantha H Wright
- Department of Speech and Language Therapy, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
| | - Wendy Blumenow
- Department of Speech and Language Therapy, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Ram Kumar
- Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Alison Felton
- Department of Speech and Language Therapy, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Siobhan McMahon
- Department of Speech and Language Therapy, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Dawn Hennigan
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Shivaram Avula
- Department of Radiology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Barry Pizer
- Department of Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
10
|
Kumar S, Islim A, Moon R, Millward C, Hennigan D, Bakhsh A, Thorpe A, Foster M, Pizer B, Mallucci C, Jenkinson M. Long Term Quality of Life Outcomes Following Surgical Resection Alone for Benign Paediatric Intracranial Tumours. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac200.031] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
AIMS
Survivors of paediatric intracranial malignancies are at increased risk of psychosocial, neuro-developmental and functional impairment, important measures of patients’ well-being. This study aimed to evaluate long-term quality of life outcomes (QOL) in patients with benign paediatric brain tumours treated curatively with surgical resection alone.
METHOD
Cross-sectional cohort study of benign paediatric intracranial tumours managed with surgery alone between 2000-2015. Validated QOL questionnaires were administered: SF-36, QLQ-BN20, QLQ-C30 and PedsQLTM.
RESULTS
Twenty-three patients participated (median age at surgery 13 years; range 1-18), twelve were male. The most common diagnosis was pilocytic astrocytoma (n=15). Median time from surgery to participation was 11 years (range 6-19). Fourteen patients achieved A-level qualifications and two obtained an undergraduate degree. Twelve patients were employed, eight were studying and three were unemployed or volunteering. Twelve patients were currently driving. QOL outcomes demonstrated significant limitation from social functioning (p=0.03) and cognitive functioning (p=0.023) compared to the general population norms. Patients also experienced increased loss of appetite (p=0.009) and symptoms of nausea and vomiting (p=0.031). Ten patients were under transitional teenager and young-adult (TYA) clinic follow-up. TYA patients achieved higher levels of education (p=0.014), were more likely to hold a driver’s license (p=0.041) and had improved physical functioning (p=0.005) compared to patients not transitioned through these services.
CONCLUSION
Childhood brain-tumour survivors are particularly vulnerable and at greater risk of developing psychological, neuro-cognitive, socialisation and physical development challenges. Early identification, comprehensive assessment and specialist TYA cancer healthcare input are vital to support these patients and improve their quality of life.
Collapse
Affiliation(s)
- Siddhant Kumar
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Abdurrahman Islim
- Department of Neurosurgery, Salford Royal NHS Foundation Trust , Manchester , UK
| | - Richard Moon
- Department of Neurosurgery, North Bristol NHS Trust , Bristol
| | - Christopher Millward
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Dawn Hennigan
- Alder Hey Children’s NHS Foundation Trust , Liverpool , UK
| | - Ali Bakhsh
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Antonia Thorpe
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Mitchell Foster
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| | - Barry Pizer
- Alder Hey Children’s NHS Foundation Trust , Liverpool , UK
| | - Conor Mallucci
- Alder Hey Children’s NHS Foundation Trust , Liverpool , UK
| | - Michael Jenkinson
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust , Liverpool , UK
| |
Collapse
|
11
|
Grønbæk JK, Laustsen AF, Toescu S, Pizer B, Mallucci C, Aquilina K, Molinari E, Hjort MA, Gumbeleviciene L, Hauser P, Pálmafy B, van Baarsen K, Hoving E, Zipfel J, Ehrstedt C, Grillner P, Callesen MT, Frič R, Wibroe M, Nysom K, Schmiegelow K, Sehested A, Mathiasen R, Juhler M. Left-handedness should not be overrated as a risk factor for postoperative speech impairment in children after posterior fossa tumour surgery: a prospective European multicentre study. Childs Nerv Syst 2022; 38:1479-1485. [PMID: 35759029 DOI: 10.1007/s00381-022-05567-8] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/07/2022] [Accepted: 05/20/2022] [Indexed: 11/03/2022]
Abstract
PURPOSE Cerebellar mutism syndrome (CMS) is a severe neurological complication of posterior fossa tumour surgery in children, and postoperative speech impairment (POSI) is the main component. Left-handedness was previously suggested as a strong risk factor for POSI. The aim of this study was to investigate the relationship between handedness and the risk of POSI. METHODS We prospectively included children (aged < 18 years) undergoing surgery for posterior fossa tumours in 26 European centres. Handedness was assessed pre-operatively and postoperative speech status was categorised as either POSI (mutism or reduced speech) or habitual speech, based on the postoperative clinical assessment. Logistic regression was used in the risk factor analysis of POSI as a dichotomous outcome. RESULTS Of the 500 children included, 37 (7%) were excluded from the present analysis due to enrolment at a reoperation; another 213 (43%) due to missing data about surgery (n = 37) and/or handedness (n = 146) and/or postoperative speech status (n = 53). Out of the remaining 250 (50%) patients, 20 (8%) were left-handed and 230 (92%) were right-handed. POSI was observed equally frequently regardless of handedness (5/20 [25%] in left-handed, 61/230 [27%] in right-handed, OR: 1.08 [95% CI: 0.40-3.44], p = 0.882), also when adjusted for tumour histology, location and age. CONCLUSION We found no difference in the risk of POSI associated with handedness. Our data do not support the hypothesis that handedness should be of clinical relevance in the risk assessment of CMS.
Collapse
Affiliation(s)
- Jonathan Kjær Grønbæk
- Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark. .,Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark.
| | - Aske Foldbjerg Laustsen
- Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark.,Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - Sebastian Toescu
- Department of Neurosurgery, Great Ormond Street Hospital for Children, Great Ormond Street, London, WC1N 3JH, UK.,Developmental Imaging and Biophysics Section, University College London Great Ormond Street Institute of Child Health, 30 Guilford St, London, WC1N 1EH, UK
| | - Barry Pizer
- University of Liverpool, Liverpool, L69 3BX, UK
| | - Conor Mallucci
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, E Prescot Rd, Liverpool, L14 5AB, UK
| | - Kristian Aquilina
- Department of Neurosurgery, Great Ormond Street Hospital for Children, Great Ormond Street, London, WC1N 3JH, UK
| | - Emanuela Molinari
- Department of Neurology, The Queen Elizabeth University Hospital, University of Glasgow, University Avenue, Glasgow, G12 8QQ, UK
| | - Magnus Aasved Hjort
- Department of Pediatric Hematology and Oncology, St Olavs Hospital, 7006, Trondheim, Norway
| | - Lingvita Gumbeleviciene
- Department of Neurology, Hospital of Lithuanian University of Health Sciences Kauno Klinikos, Eiveniu 2, 50161, Kaunas, Lithuania
| | - Peter Hauser
- 2nd Dept of Pediatrics, Semmelweis University, Tűzoltó u. 7-9, 1094, Budapest, Hungary.,Velkey László Child's Health Center, BAZ County Central Hospital and University Teaching Hospital, Szentpéteri kapu 72-76, 3526, Miskolc, Hungary
| | - Beatrix Pálmafy
- National Institute of Neuroscience, Amerikai út 57, 1145, Budapest, Hungary
| | - Kirsten van Baarsen
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands
| | - Eelco Hoving
- Princess Máxima Center for Pediatric Oncology, Heidelberglaan 25, 3584 CS, Utrecht, The Netherlands
| | - Julian Zipfel
- Department of Neurosurgery, Pediatric Neurosurgery, University Hospital Tuebingen, Hoppe-Seyler-Str. 3, 72076, Tuebingen, Germany
| | - Christoffer Ehrstedt
- Department of Women's and Children's Health, Uppsala University, Uppsala University Children's Hospital, 751 85, Uppsala, Sweden
| | - Pernilla Grillner
- Pediatric Oncology Unit, Astrid Lindgren's Children's Hospital, 6 Karolinska vägen, 171 76, Stockholm, Sweden
| | - Michael Thude Callesen
- Department of Pediatric Oncology and Haematology, H.C. Andersen Children's Hospital, Kløvervænget 23C, 5000, Odense, Denmark
| | - Radek Frič
- Department of Neurosurgery, Oslo University Hospital, Postboks 4950 Nydalen, 0424, Oslo, Norway
| | - Morten Wibroe
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - Karsten Nysom
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - Kjeld Schmiegelow
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark.,Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark
| | - Astrid Sehested
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - René Mathiasen
- Department of Paediatrics and Adolescent Medicine, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark
| | - Marianne Juhler
- Department of Neurosurgery, Copenhagen University Hospital Rigshospitalet, Blegdamsvej 9, 2100, Copenhagen E, Denmark.,Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Blegdamsvej 3B, 2200, Copenhagen, Denmark.,Department of Neurosurgery, Aarhus University Hospital, Palle Juul-Jensens, Boulevard 99, 8200, Aarhus, Denmark
| | | |
Collapse
|
12
|
Shabo E, Czech T, Nicholson JC, Mallucci C, Mottolese C, Piatelli G, Frappaz D, Murray MJ, Faure-Conter C, Garrè ML, Sarikaya-Seiwert S, Weinhold L, Haberl H, Calaminus G. Evaluation of the Perioperative and Postoperative Course of Surgery for Pineal Germinoma in the SIOP CNS GCT 96 Trial. Cancers (Basel) 2022; 14:cancers14143555. [PMID: 35884617 PMCID: PMC9323477 DOI: 10.3390/cancers14143555] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2022] [Revised: 07/16/2022] [Accepted: 07/18/2022] [Indexed: 02/05/2023] Open
Abstract
Background: CNS germinoma, being marker-negative, are mainly diagnosed by histological examination. These tumors predominantly appear in the suprasellar and/or pineal region. In contrast to the suprasellar region, where biopsy is the standard procedure in case of a suspected germ-cell tumor to avoid mutilation to the endocrine structures, pineal tumors are more accessible to primary resection. We evaluated the perioperative course of patients with pineal germinoma who were diagnosed by primary biopsy or resection in the SIOP CNS GCT 96 trial. Methods: Overall, 235 patients had germinoma, with pineal localization in 113. The relationship between initial symptoms, tumor size, and postoperative complications was analyzed. Results: Of 111 evaluable patients, initial symptoms were headache (n = 98), hydrocephalus (n = 93), double vision (n = 62), Parinaud syndrome (n = 57), and papilledema (n = 44). There was no significant relationship between tumor size and primary symptoms. A total of 57 patients underwent primary resection and 54 underwent biopsy. Postoperative complications were reported in 43.2% of patients after resection and in 11.4% after biopsy (p < 0.008). Biopsy was significantly more commonly performed on larger tumors (p= 0.002). Conclusions: These results support the practice of biopsy over resection for histological confirmation of pineal germinoma.
Collapse
Affiliation(s)
- Ehab Shabo
- Department of Neurosurgery, Rheinische Friedrich-Wilhelms-University, Sigmund-Freud-Straße 25, 53127 Bonn, Germany
- Correspondence: ; Tel.: +49-228-287-16521; Fax: +49-228-287-11366
| | - Thomas Czech
- Department of Neurosurgery, Medical University of Vienna, 1090 Vienna, Austria;
| | - James C. Nicholson
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge CB2 0QQ, UK;
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children’s Hospital, Liverpool L14 5AB, UK; (C.M.); (M.J.M.)
| | - Carmine Mottolese
- Neurochirurgie Pédiatrique, Hôpital Femme-Mère-Enfant, Université de Lyon, 59, Boulevard Pinel, 69003 Lyon, France;
| | - Gianluca Piatelli
- Division of Neurosurgery, Department of Neurosciences, Giannina Gaslini Children’s Hospital, 16147 Genvoa, Italy;
| | - Didier Frappaz
- Department of Pediatric Hematology and Oncology, Institut d’Hématologie et d’Oncologie Pédiatrique, 69008 Lyon, France; (D.F.); (C.F.-C.)
| | - Matthew Jonathan Murray
- Department of Neurosurgery, Alder Hey Children’s Hospital, Liverpool L14 5AB, UK; (C.M.); (M.J.M.)
- Department of Pathology, University of Cambridge, Tennis Court Road, Cambridge CB2 1QP, UK
| | - Cecile Faure-Conter
- Department of Pediatric Hematology and Oncology, Institut d’Hématologie et d’Oncologie Pédiatrique, 69008 Lyon, France; (D.F.); (C.F.-C.)
| | - Maria Luisa Garrè
- Department of Pediatric Hematology-Oncology and Bone Marrow Transplantation, IRCCS Istituto Giannina Gaslini, 16147 Genova, Italy;
| | - Sevgi Sarikaya-Seiwert
- Section of Pediatric Neurosurgery, Department of Neurosurgery, Rheinische, Friedrich-Wilhelms-University, Sigmund-Freud-Straße 25, 53127 Bonn, Germany; (S.S.-S.); (H.H.)
| | - Leonie Weinhold
- Department of Medical Biometry, Informatics and Epidemiology, University Hospital Bonn, 53127 Bonn, Germany;
| | - Hannes Haberl
- Section of Pediatric Neurosurgery, Department of Neurosurgery, Rheinische, Friedrich-Wilhelms-University, Sigmund-Freud-Straße 25, 53127 Bonn, Germany; (S.S.-S.); (H.H.)
| | - Gabriele Calaminus
- Department of Pediatric Hematology and Oncology, University Hospital Bonn, Venusberg-Campus 1, 53127 Bonn, Germany;
| |
Collapse
|
13
|
Trichinopoly Krishna S, Millward C, Mallucci C, Gamble C, Jenkinson M, Pizer B. SURG-13. The COMBAT Project - Core post operative morbidity set for paediatric brain tumours. Neuro Oncol 2022. [DOI: 10.1093/neuonc/noac079.531] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
BACKGROUND: Brain tumours are associated with high morbidity both from the tumour and the medical and surgical interventions used to treat them. Post operative morbidity reporting following surgery for paediatric brain tumours is poor due to the lack of a common language when reporting harms. One solution is to develop a core adverse outcome set to stipulate the minimum post operative harms that should be reported. The COMBAT (Core post operative morbidity set for paediatric brain tumours) Project will develop a core adverse outcome set that can be applied to post operative paediatric brain tumour patients to harmonise how harms are measured and reported, enabling comparison between different trials, studies and clinical services. We aim to generate interest in the COMBAT Project and invite collaboration with healthcare professionals and researchers experienced in paediatric neuro oncology surgery. METHODS AND ANALYSIS : A systematic review will identify harms reported in post operative paediatric brain tumour patients and how they are measured. We will engage with national and international stakeholders including healthcare professionals, researchers, patients and their carers. Qualitative interviews with patients and carers will identify any important harms not extracted in the systematic review. A Delphi survey will be created from the harms identified. An international consensus meeting will be held to finalise the core adverse outcomes set. The final core adverse outcome set will be published and disseminated to encourage uptake. DISCUSSION: There is a clear need for a common language to harmonise measurement and reporting of harms following surgery for paediatric brain tumour patients. The core adverse outcome set will be developed with collaboration with key stakeholder groups to ensure it is representative. It will be used to standardise surgical morbidity outcome measurement and reporting in trials, studies and clinical practice and will inform future research in this field.
Collapse
Affiliation(s)
- Sandhya Trichinopoly Krishna
- Alder Hey Children's NHS Foundation Trust , Liverpool , United Kingdom
- The Walton Centre NHS Foundation Trust , Liverpool , United Kingdom
| | - Christopher Millward
- The Walton Centre NHS Foundation Trust , Liverpool , United Kingdom
- University of Liverpool , Liverpool , United Kingdom
| | - Conor Mallucci
- Alder Hey Children's NHS Foundation Trust , Liverpool , United Kingdom
| | - Carrol Gamble
- University of Liverpool , Liverpool , United Kingdom
| | - Michael Jenkinson
- The Walton Centre NHS Foundation Trust , Liverpool , United Kingdom
- University of Liverpool , Liverpool , United Kingdom
| | - Barry Pizer
- Alder Hey Children's NHS Foundation Trust , Liverpool , United Kingdom
| |
Collapse
|
14
|
Ritzmann TA, Chapman RJ, Kilday JP, Thorp N, Modena P, Dineen RA, Macarthur D, Mallucci C, Jaspan T, Pajtler KW, Giagnacovo M, Jacques TS, Paine SML, Ellison DW, Bouffet E, Grundy RG. SIOP Ependymoma I: Final results, long-term follow-up, and molecular analysis of the trial cohort-A BIOMECA Consortium Study. Neuro Oncol 2022; 24:936-948. [PMID: 35018471 PMCID: PMC9159435 DOI: 10.1093/neuonc/noac012] [Citation(s) in RCA: 15] [Impact Index Per Article: 7.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
BACKGROUND SIOP Ependymoma I was a non-randomised trial assessing event free and overall survival (EFS/OS) of non-metastatic intracranial ependymoma in children aged 3-21 years treated with a staged management strategy. A further aim was to assess the response rate (RR) of subtotally resected (STR) ependymoma to vincristine, etoposide, and cyclophosphamide (VEC). We report final results with 12-year follow-up and post hoc analyses of recently described biomarkers. METHODS Seventy-four participants were eligible. Children with gross total resection (GTR) received radiotherapy, whilst those with STR received VEC before radiotherapy. DNA methylation, 1q, hTERT, ReLA, Tenascin-C, H3K27me3, and pAKT status were evaluated. RESULTS Five- and ten-year EFS was 49.5% and 46.7%, OS was 69.3% and 60.5%. GTR was achieved in 33/74 (44.6%) and associated with improved EFS (P = .003, HR = 2.6, 95% confidence interval (CI) 1.4-5.1). Grade 3 tumours were associated with worse OS (P = .005, HR = 2.8, 95%CI 1.3-5.8). 1q gain and hTERT expression were associated with poorer EFS (P = .003, HR = 2.70, 95%CI 1.49-6.10 and P = .014, HR = 5.8, 95%CI 1.2-28) and H3K27me3 loss with worse OS (P = .003, HR = 4.6, 95%CI 1.5-13.2). Methylation profiles showed expected patterns. 12 participants with STR did not receive chemotherapy; a protocol violation. However, best chemotherapy RR was 65.5% (19/29, 95%CI 45.7-82.1), exceeding the prespecified 45%. CONCLUSIONS Participants with totally resected ependymoma had the best outcomes. RR of STR to VEC exceeded the pre-specified efficacy criterion. However, cases of inaccurate stratification highlighted the need for rapid central review. 1q gain, H3K27me3 loss, and hTERT expression were all associated with poorer survival outcomes.
Collapse
Affiliation(s)
- Timothy A Ritzmann
- Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Rebecca J Chapman
- Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
| | - John-Paul Kilday
- Children’s Brain Tumour Research Network (CBTRN), Royal Manchester Children’s Hospital, Manchester, UK
- The Centre for Paediatric, Teenage and Young Adult Cancer, University of Manchester, Manchester, UK
| | - Nicola Thorp
- The Clatterbridge Cancer Centre, Liverpool, UK
- The Christie Hospital Proton Beam Therapy Centre, Manchester, UK
| | | | - Robert A Dineen
- Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
- NIHR Nottingham Biomedical Research Centre, Nottingham, UK
| | - Donald Macarthur
- Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Conor Mallucci
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - Timothy Jaspan
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Kristian W Pajtler
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neuro-oncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
- Department of Pediatric Oncology, Hematology, and Immunology, University Hospital Heidelberg, Heidelberg, Germany
| | | | - Thomas S Jacques
- UCL GOS Institute of Child Health, London, UK
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Simon M L Paine
- Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - David W Ellison
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - Eric Bouffet
- The Hospital for Sick Children, Toronto, Ontario, Canada
| | - Richard G Grundy
- Children’s Brain Tumour Research Centre, University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| |
Collapse
|
15
|
Apps JR, Maycock S, Ellison DW, Jaspan T, Ritzmann TA, Macarthur D, Mallucci C, Wheatley K, Veal GJ, Grundy RG, Picton S. Phase II study of intravenous etoposide in patients with relapsed ependymoma (CNS 2001 04). Neurooncol Adv 2022; 4:vdac053. [PMID: 35591977 PMCID: PMC9113139 DOI: 10.1093/noajnl/vdac053] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Background Relapsed ependymoma has a dismal prognosis, and the role of chemotherapy at relapse remains unclear. This study prospectively evaluated the efficacy of intensive intravenous (IV) etoposide in patients less than 21 years of age with relapsed intracranial ependymoma (NCT00278252). Methods This was a single-arm, open-label, phase II trial using Gehan's two-stage design. Patients received IV etoposide 100 mg/m2 on days 1-3, 8-10, and 15-17 of each 28-day cycle, up to maximum of 6 cycles. Primary outcome was radiological response after 3 cycles. Pharmacokinetic analysis was performed in 10 patients. Results Twenty-five patients were enrolled and included in the intention-to-treat (ITT) analysis. Three patients were excluded in per-protocol (PP) analysis. After 3 cycles of etoposide, 5 patients (ITT 20%/PP 23%) had a complete response (CR), partial response (PR), or objective response (OR). Nine patients (ITT 36%/PP 41%,) had a best overall response of CR, PR, or OR. 1-year PFS was 24% in ITT and 23% in PP populations. 1-year OS was 56% and 59%, 5-year OS was 20% and 18%, respectively, in ITT and PP populations. Toxicity was predominantly hematological, with 20/25 patients experiencing a grade 3 or higher hematological adverse event. Conclusions This study confirms the activity of IV etoposide against relapsed ependymoma, however, this is modest, not sustained, and similar to that with oral etoposide, albeit with increased toxicity. These results confirm the dismal prognosis of this disease, provide a rationale to include etoposide within drug combinations, and highlight the need to develop novel treatments for recurrent ependymoma.
Collapse
Affiliation(s)
- John R Apps
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - Shanna Maycock
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - David W Ellison
- Department of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, USA
| | - Timothy Jaspan
- Radiology Department, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Timothy A Ritzmann
- Children’s Brain Tumour Research Centre, Bio-Discovery Institute and Queen’s Medical Centre, University of Nottingham, Nottingham, UK
| | - Donald Macarthur
- Children’s Brain Tumour Research Centre, Bio-Discovery Institute and Queen’s Medical Centre, University of Nottingham, Nottingham, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - Keith Wheatley
- Cancer Research UK Clinical Trials Unit, University of Birmingham, Birmingham, UK
| | - Gareth J Veal
- Newcastle University Centre for Cancer, Newcastle University, Newcastle upon Tyne, UK
| | - Richard G Grundy
- Children’s Brain Tumour Research Centre, Bio-Discovery Institute and Queen’s Medical Centre, University of Nottingham, Nottingham, UK
| | - Susan Picton
- Department of Paediatric Oncology, Leeds Children’s Hospital, The Leeds Teaching Hospitals NHS Trust, Leeds, UK
| |
Collapse
|
16
|
Gillespie CS, Richardson GE, Mustafa MA, Evans D, George AM, Islim AI, Mallucci C, Jenkinson MD, McMahon CJ. How should we treat long-standing overt ventriculomegaly in adults (LOVA)? A retrospective cohort study. Neurosurg Rev 2022; 45:3193-3200. [PMID: 35688957 PMCID: PMC9492616 DOI: 10.1007/s10143-022-01812-5] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/19/2022] [Revised: 04/16/2022] [Accepted: 05/10/2022] [Indexed: 02/03/2023]
Abstract
Long-standing overt ventriculomegaly in adults (LOVA) is a heterogenous group of conditions with differing presentations. Few studies have evaluated success rates of available surgical treatments, or ascertained the natural history. There is a need to assess the efficacy of both endoscopic third ventriculostomy (ETV) and ventriculoperitoneal shunt (VPS) as first-line treatments. We conducted a retrospective, single-centre study of adults with LOVA at a tertiary neurosurgery centre in England, UK, aiming to identify presentation, management strategy, and outcome following treatment. A total of 127 patients were included (mean age 48.1 years, 61/127 male). Most patients were symptomatic (73.2%, n = 93/127, median symptom duration 10 months). The most common symptoms were gait ataxia, headache, and cognitive decline (52.8%, 50.4%, and 33.9%, respectively). Fourteen patients had papilloedema. Ninety-one patients (71.7%) underwent surgery (84 ETV, 7 VPS). Over a median follow-up of 33.0 months (interquartile range [IQR] 19.0-65.7), 82.4% had a clinical improvement after surgery, and 81.3% had radiological improvement. Clinical improvement rates were similar between ETV and VP shunt groups (82.1% vs 85.7%, p = 0.812). Surgical complication rates were significantly lower in the ETV group than the VP shunt group (4.8% vs 42.9%, p < 0.001). Of the patients treated surgically, 20 (22.0%) underwent further surgery, with 14 patients improving. This study demonstrates the efficacy of ETV as a first-line treatment for LOVA.
Collapse
Affiliation(s)
- Conor S. Gillespie
- Institute of Systems, Molecular and Integrative Biology, School of Medicine, University of Liverpool, Cedar House, Ashton Street, Liverpool, L69 3GE UK ,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - George E. Richardson
- Institute of Systems, Molecular and Integrative Biology, School of Medicine, University of Liverpool, Cedar House, Ashton Street, Liverpool, L69 3GE UK ,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Mohammad A. Mustafa
- Institute of Systems, Molecular and Integrative Biology, School of Medicine, University of Liverpool, Cedar House, Ashton Street, Liverpool, L69 3GE UK ,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Daisy Evans
- School of Medicine, Keele University, Staffordshire, UK
| | - Alan M. George
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK ,School of Medicine, University of Birmingham, Birmingham, UK
| | - Abdurrahman I. Islim
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - Michael D. Jenkinson
- Institute of Systems, Molecular and Integrative Biology, School of Medicine, University of Liverpool, Cedar House, Ashton Street, Liverpool, L69 3GE UK ,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Catherine J. McMahon
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
17
|
Grønbæk JK, Wibroe M, Toescu S, Frič R, Thomsen BL, Møller LN, Grillner P, Gustavsson B, Mallucci C, Aquilina K, Fellows GA, Molinari E, Hjort MA, Westerholm-Ormio M, Kiudeliene R, Mudra K, Hauser P, van Baarsen K, Hoving E, Zipfel J, Nysom K, Schmiegelow K, Sehested A, Juhler M, Mathiasen R. Postoperative speech impairment and surgical approach to posterior fossa tumours in children: a prospective European multicentre cohort study. Lancet Child Adolesc Health 2021; 5:814-824. [PMID: 34624241 DOI: 10.1016/s2352-4642(21)00274-1] [Citation(s) in RCA: 25] [Impact Index Per Article: 8.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2021] [Revised: 07/16/2021] [Accepted: 08/17/2021] [Indexed: 12/29/2022]
Abstract
BACKGROUND Brain tumours are the most common solid tumours in childhood. Half of these tumours occur in the posterior fossa, where surgical removal is complicated by the risk of cerebellar mutism syndrome, of which postoperative speech impairment (POSI) is a cardinal symptom, in up to 25% of patients. The surgical approach to midline tumours, mostly undertaken by transvermian or telovelar routes, has been proposed to influence the risk of POSI. We aimed to investigate the risk of developing POSI, the time course of its resolution, and its association with surgical approach and other clinical factors. METHODS In this observational prospective multicentre cohort study, we included children (aged <18 years) undergoing primary surgery for a posterior fossa tumour at 26 centres in nine European countries. Within 72 h of surgery, the operating neurosurgeon reported details on the tumour location, surgical approach used, duration of surgery, use of traction, and other predetermined factors, using a standardised surgical report form. At 2 weeks, 2 months, and 1 year after surgery, a follow-up questionnaire was filled out by a paediatrician or neurosurgeon, including neurological examination and assessment of speech. Speech was classified as mutism, reduced speech, or habitual speech. POSI was defined as either mutism or severely reduced speech. Ordinal logistic regression was used to analyse the risk of POSI. FINDINGS Between Aug 11, 2014, and Aug 24, 2020, we recruited 500 children. 426 (85%) patients underwent primary tumour surgery and had data available for further analysis. 192 (45%) patients were female, 234 (55%) patients were male, 81 (19%) patients were aged 0-2 years, 129 (30%) were aged 3-6 years, and 216 (51%) were aged 7-17 years. 0f 376 with known postoperative speech status, 112 (30%) developed POSI, 53 (14%) developed mutism (median 1 day [IQR 0-2]; range 0-10 days), and 59 (16%) developed reduced speech after surgery (0 days [0-1]; 0-4 days). Mutually adjusted analyses indicated that the independent risk factors for development of POSI were younger age (linear spline, p=0·0087), tumour location (four levels, p=0·0010), and tumour histology (five levels, p=0·0030); surgical approach (six levels) was not a significant risk factor (p=0·091). Tumour location outside the fourth ventricle and brainstem had a lower risk of POSI (with fourth ventricle as reference, odds ratio (OR) for cerebellar vermis 0·34 [95% CI 0·14-0·77] and OR for cerebellar hemispheres 0·23 [0·07-0·70]). Compared with pilocytic or pilomyxoid astrocytoma, a higher risk of POSI was seen for medulloblastoma (OR 2·85 [1·47-5·60]) and atypical teratoid rhabdoid tumour (10·30 [2·10-54·45]). We did not find an increased risk of POSI for transvermian surgical approach compared with telovelar (0·89 [0·46-1·73]). Probability of speech improvement from mutism reached 50% around 16 days after mutism onset. INTERPRETATION Our data suggest that a midline tumour location, younger age, and high-grade tumour histology all increase the risk of speech impairment after posterior fossa tumour surgery. We found no evidence to recommend a preference for telovelar over transvermian surgical approach in the management of posterior fossa tumours in children in relation to the risk of developing POSI. FUNDING The Danish Childhood Cancer Foundation, the Swedish Childhood Cancer Foundation, the UK Brain Tumour Charity, the Danish Cancer Society, Det Kgl Kjøbenhavnske Skydeselskab og Danske Broderskab, the Danish Capitol Regions Research Fund, Dagmar Marshall Foundation, Rigshospitalet's Research Fund, and Brainstrust.
Collapse
Affiliation(s)
- Jonathan Kjær Grønbæk
- Department of Neurosurgery, The University Hospital Rigshospitalet, Copenhagen, Denmark; Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Morten Wibroe
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Sebastian Toescu
- Department of Neurosurgery, Great Ormond Street Hospital for Children, London, UK; Developmental Imaging and Biophysics Section, University College London Great Ormond Street Institute of Child Health, London, UK
| | - Radek Frič
- Department of Neurosurgery, Oslo University Hospital, Oslo, Norway
| | | | - Lisbeth Nørgaard Møller
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Pernilla Grillner
- Pediatric Oncology Unit, Astrid Lindgrens Childrens Hospital, Karolinska University Hospital, Stockholm, Sweden
| | - Bengt Gustavsson
- Department of Neurosurgery, Karolinska University Hospital, Stockholm, Sweden
| | - Conor Mallucci
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Kristian Aquilina
- Department of Neurosurgery, Great Ormond Street Hospital for Children, London, UK
| | - Greg Adam Fellows
- Department of Paediatric Neurosurgery, Bristol Royal Hospital for Children, Bristol, UK
| | - Emanuela Molinari
- Department of Neurology, The Queen Elizabeth University Hospital, University of Glasgow, Glasgow, UK
| | - Magnus Aasved Hjort
- Department of Pediatric Hematology and Oncology, St Olavs Hospital, Trondheim, Norway
| | | | - Rosita Kiudeliene
- Center of Pediatric Oncology and Hematology at Pediatric Department and Hospital of Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Katalin Mudra
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Peter Hauser
- 2nd Department of Pediatrics, Semmelweis University, Budapest, Hungary; Pediatric Oncology and Transplantation Unit, Velkey László Child's Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital, Miskolc, Hungary
| | | | - Eelco Hoving
- Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands
| | - Julian Zipfel
- Division of Pediatric Neurosurgery, Department of Neurosurgery, University Hospital Tübingen, Tübingen, Germany
| | - Karsten Nysom
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Kjeld Schmiegelow
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark; Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Astrid Sehested
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Marianne Juhler
- Department of Neurosurgery, The University Hospital Rigshospitalet, Copenhagen, Denmark; Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark; Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark
| | - René Mathiasen
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark.
| | | |
Collapse
|
18
|
Richardson GE, Islim AI, Albanese E, Ahmed A, Aly A, Ammar A, Amoo M, Bhatt H, Bodkin P, Coulter I, Corr P, Elmaadawi I, Elserius A, Fountain DM, George KJ, Gillespie CS, Goel A, Grundy PL, Gurusinghe N, Hartley J, Hasan MT, Javadpour M, Kalra N, Mallucci C, Millward CP, Mohamed B, Mohamed S, Mustafa MA, Nannapaneni R, Nolan D, Patel UJ, Piper RJ, Rajaraman C, Raza-Knight S, Rehman K, Rominiyi O, Sage W, Sharouf F, Sinha S, Sitaraman M, Smith S, Solth A, Stokes S, Taweel BA, Tyagi A, Zaben M, Jenkinson MD, Prasad M. Neurosurgery activity levels in the United Kingdom and republic of Ireland during the first wave of the covid-19 pandemic - a retrospective cross-sectional cohort study. Br J Neurosurg 2021:1-6. [PMID: 34472417 DOI: 10.1080/02688697.2021.1968341] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2021] [Revised: 06/11/2021] [Accepted: 08/09/2021] [Indexed: 12/27/2022]
Abstract
The impact of Covid-19 on surgical patients worldwide has been substantial. In the United Kingdom (UK) and the Republic of Ireland (RoI), the first wave of the pandemic occurred in March 2020. The aims of this study were to: (1) evaluate the volume of neurosurgical operative activity levels, Covid-19 infection rate and mortality rate in April 2020 with a retrospective cross-sectional cohort study conducted across 16 UK and RoI neurosurgical centres, and (2) compare patient outcomes in a single institution in April-June 2020 with a comparative cohort in 2019. Across the UK and RoI, 818 patients were included. There were 594 emergency and 224 elective operations. The incidence rate of Covid-19 infection was 2.6% (21/818). The overall mortality rate in patients with a Covid-19 infection was 28.6% (6/21). In the single centre cohort analysis, an overall reduction in neurosurgical operative activity by 65% was observed between 2020 (n = 304) and 2019 (n = 868). The current and future impact on UK neurosurgical operative activity has implications for service delivery and neurosurgical training.
Collapse
Affiliation(s)
- George E Richardson
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Abdurrahman I Islim
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Erminia Albanese
- Department of Neurosurgery, North Staffordshire Hospital Trust, Stoke on Trent, UK
| | - Ahmed Ahmed
- Department of Neurosurgery, Aberdeen Royal Infirmary, Aberdeen, UK
| | - Ahmed Aly
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Amr Ammar
- Department of Neurosurgery, Queen's Medical Centre, Nottingham, UK
| | - Michael Amoo
- Department of Neurosurgery, Beaumont Hospital, Dublin, Republic of Ireland
| | - Harsh Bhatt
- Department of Neurosurgery, University Hospital of Wales, Cardiff, UK
| | - Peter Bodkin
- Department of Neurosurgery, Aberdeen Royal Infirmary, Aberdeen, UK
| | - Ian Coulter
- Department of Neurosurgery, Royal Victoria Infirmary, Newcastle upon Tyne, UK
| | - Paula Corr
- Department of Neurosurgery, Beaumont Hospital, Dublin, Republic of Ireland
| | | | - Anne Elserius
- Department of Neurosurgery, North Staffordshire Hospital Trust, Stoke on Trent, UK
| | - Daniel M Fountain
- Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK
| | - K Joshi George
- Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK
| | - Conor S Gillespie
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Aimee Goel
- Department of Neurosurgery, North Staffordshire Hospital Trust, Stoke on Trent, UK
| | - Paul L Grundy
- Wessex Neurological Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | | | - Jessica Hartley
- Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK
| | - Md Tanvir Hasan
- Manchester Centre for Clinical Neurosciences, Salford Royal NHS Foundation Trust, Salford, UK
| | - Mohsen Javadpour
- Department of Neurosurgery, Beaumont Hospital, Dublin, Republic of Ireland
| | - Neeraj Kalra
- Department of Neurosurgery, Leeds General Infirmary, Leeds, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Christopher P Millward
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Belal Mohamed
- Department of Neurosurgery, Royal Victoria Infirmary, Newcastle upon Tyne, UK
| | - Saffwan Mohamed
- Department of Neurosurgery, The James Cook University Hospital, Middlesbrough, UK
| | - Mohammad A Mustafa
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | | | - Deirdre Nolan
- Department of Neurosurgery, Beaumont Hospital, Dublin, Republic of Ireland
| | - Umang J Patel
- Department of Neurosurgery, John Radcliffe Hospital, Oxford, UK
| | - Rory J Piper
- Department of Neurosurgery, John Radcliffe Hospital, Oxford, UK
| | | | | | - Kafeel Rehman
- Department of Neurosurgery, Hull Royal Infirmary, Hull, UK
| | - Ola Rominiyi
- Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK
| | - William Sage
- Department of Neurosurgery, Queen's Medical Centre, Nottingham, UK
| | - Feras Sharouf
- Department of Neurosurgery, University Hospital of Wales, Cardiff, UK
| | - Saurabh Sinha
- Department of Neurosurgery, Royal Hallamshire Hospital, Sheffield, UK
| | | | - Stuart Smith
- Department of Neurosurgery, Queen's Medical Centre, Nottingham, UK
| | - Anna Solth
- Department of Neurosurgery, Ninewells Hospital, Dundee, UK
| | - Stuart Stokes
- Department of Neurosurgery, Hull Royal Infirmary, Hull, UK
| | - Basel A Taweel
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Atul Tyagi
- Department of Neurosurgery, Leeds General Infirmary, Leeds, UK
| | - Malik Zaben
- Department of Neurosurgery, University Hospital of Wales, Cardiff, UK
| | - Michael D Jenkinson
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Liverpool, UK
| | - Manjunath Prasad
- Department of Neurosurgery, The James Cook University Hospital, Middlesbrough, UK
| |
Collapse
|
19
|
Sunderland G, Foster MT, Pizer B, Hennigan D, Pettorini B, Mallucci C. Evolution of surgical attitudes to paediatric thalamic tumours: the alder hey experience. Childs Nerv Syst 2021; 37:2821-2830. [PMID: 34128121 DOI: 10.1007/s00381-021-05223-7] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/29/2021] [Accepted: 05/20/2021] [Indexed: 11/24/2022]
Abstract
PURPOSE Attitudes to surgery for paediatric thalamic tumours have evolved due to improved preoperative imaging modalities and the advent of intraoperative MRI (iMRI) as well as enhanced understanding of tumour biology. We review the developments in our local practice over the last three decades with particular attention to the impact of iMRI. METHODS We identified all paediatric patients from a prospectively maintained neuro-oncology database who received surgery for a thalamic tumour (n = 30). All children were treated in a single UK tertiary paediatric neurosurgery centre between January 1991 and June 2020. Twenty patients underwent surgical resection, the remainder (10) undergoing biopsy only. Pre-operative surgical intent (biopsy versus debulking, near-total resection, or complete resection) as well as the use of iMRI were prospectively recorded. Complications recorded in clinical documentation between postoperative days 0 and 30 were retrospectively graded using a modified version of the Clavien Dindo scale. The extent of resection with respect to the pre-determined surgical aim was also recorded. Data on patient survival and disease progression status were obtained retrospectively. RESULTS In our series, there were 42 procedures (25 craniotomies, 17 biopsies) performed on 30 patients (17 male, with a median age of 8 at surgery). Of the 25 surgical resections performed, complete resection was achieved in 9 (36%), near-total resection in 10 (40%), and limited debulking in 6 (24%). The predetermined surgical aim was achieved or exceeded in 91.3% of cases. The proportion of craniotomies for which substantial resection was achieved, increased from 37.5 to 94.2% with use of iMRI (p = 0.014). Surgical morbidity was not associated with greater extent of surgical resection. High-grade histology is identified as the only independent significant factor influencing overall survival as calculated by Cox proportional hazards model (p = 0.006). CONCLUSION We note a significant change in the rate and extent of attempted resection of paediatric thalamic tumours that has developed over the last 3 decades. Use of iMRI is associated with a significant increase in substantial tumour resection surgeries. This is not associated with any significant level of surgical morbidity. Improvements in pre- and intra-operative imaging alongside better understanding of tumour biology facilitate patient selection and a surgically more aggressive approach in selected cases whilst maintaining safety and avoiding operative morbidity.
Collapse
Affiliation(s)
- Geraint Sunderland
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.
| | - Mitchell T Foster
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,Cancer Research UK Brain Tumour Centre of Excellence, The University of Edinburgh, Edinburgh, UK
| | - Barry Pizer
- Department of Paediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Dawn Hennigan
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Benedetta Pettorini
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
20
|
Millward CP, Van Tonder L, Williams D, Thornton O, Foster M, Griffiths M, Puthuran M, Chandran A, Israni A, Sinha A, Kneen R, Mallucci C. Screening for cerebrovascular disorder on the basis of family history in asymptomatic children. Br J Neurosurg 2021; 35:584-590. [PMID: 34169790 DOI: 10.1080/02688697.2021.1922607] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022]
Abstract
Background: Cerebrovascular disorders represent a group of uncommon, heterogeneous, and complex conditions in children. We reviewed the screening practice for the detection of cerebrovascular disorder in asymptomatic children referred to our neurovascular service on the basis of a positive family history and parental and/or treating physician concern.Methods: Retrospective case-note review of referrals to our neurovascular service (July 2008-April 2018). Patients were included if the referral was made for screening, on the basis of a positive family history of cerebrovascular disorder. Symptomatic children, those with previous cranial imaging, or children under the care of a clinical geneticist (i.e. due to the child or their relative having HHT or mutations in KRIT1) were not eligible for inclusion.Results: Forty-one children were reviewed, 22 males (Median age 10.7 years, range 0.6-15.6 years). This represented 22% of the total number of referrals over a 10-year period. Twenty-nine children had an MRI/MRA brain. Twenty-eight children were referred due to a family history of intracranial aneurysm and/or subarachnoid haemorrhage, but only two had two first-degree relatives affected. Ten children were referred due to a family history of arteriovenous malformation. Three children were referred due to a family history of stroke. No cerebrovascular disease was detected during the study period (n = 29).Conclusions: Parental and/or physician concern generated a substantial number of referrals but no pathology was detected after screening. Whilst general screening guidance exists for the detection of intracranial aneurysms, consensus guidelines for the screening of children with a positive family history do not, but are required both to guide clinical practice and to assuage parental and/or physician concerns.
Collapse
Affiliation(s)
- Christopher Paul Millward
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK.,University of Liverpool, Liverpool, UK
| | - Libby Van Tonder
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,University of Liverpool, Liverpool, UK
| | - Dawn Williams
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Owen Thornton
- Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Mitchell Foster
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Michael Griffiths
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,University of Liverpool, Liverpool, UK
| | - Mani Puthuran
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Arun Chandran
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Anil Israni
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Ajay Sinha
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,Department of Neurosurgery, The Walton Centre NHS Foundation Trust, Liverpool, UK
| | - Rachel Kneen
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,University of Liverpool, Liverpool, UK
| | - Conor Mallucci
- Neurosurgery Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK.,University of Liverpool, Liverpool, UK
| |
Collapse
|
21
|
A. Ritzmann T, Chapman RJ, Macarthur D, Mallucci C, Kilday JP, Thorp N, Modena P, Giagnacovo M, Dineen R, Jaspan T, Pajtler KW, Jacques TS, Paine SML, Ellison DW, Bouffet E, Grundy RG. EPEN-04. SIOP EPENDYMOMA I: FINAL RESULTS, LONG TERM FOLLOW-UP AND MOLECULAR ANALYSIS OF THE TRIAL COHORT: A BIOMECA CONSORTIUM STUDY. Neuro Oncol 2021. [PMCID: PMC8168242 DOI: 10.1093/neuonc/noab090.054] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022] Open
Abstract
Introduction Surgery and radiotherapy are established childhood ependymoma treatments. The efficacy of chemotherapy has been debated. We report final results of the SIOP Ependymoma I trial, with 12-year follow-up, in the context of a post-hoc analysis of more recently described biomarkers. Aims and Methods The trial assessed event free (EFS) and overall survival (OS) of patients aged three to 21 years with non-metastatic intracranial ependymoma, treated with a staged management strategy targeting maximum local control. The study also assessed: the response rate (RR) of subtotally resected (STR) disease to vincristine, etoposide and cyclophosphamide (VEC); and surgical operability. Children with gross total resection (GTR) received radiotherapy of 54 Gy in 30 daily fractions over six weeks, whilst those with STR received VEC before radiotherapy. We retrospectively assessed methylation and 1q status alongside hTERT, RELA, Tenascin C, H3K27me3 and pAKT expression. Results Between 1999 and 2007, 89 participants were enrolled, 15 were excluded with metastatic (n=4) or non-ependymoma tumours (n=11) leaving a final cohort of 74. Five- and ten-year EFS was 49.5% and 46.7%, OS was 69.3% and 60.5%. 1q gain was associated with poorer EFS (p=0.002, HR=3.00, 95%CI 1.49–6.10). hTERT expression was associated with worse five-year EFS (20.0% Vs 83.3%, p=0.014, HR=5.8). GTR was achieved in 33/74 (44.6%) and associated with improved EFS (p=0.006, HR=2.81, 95% confidence interval 1.35–5.84). There was an improvement in GTR rates in the latter half of the trial (1999-2002 32.4% versus 2003-2007 56.8%). Despite the protocol, 12 participants with STR did not receive chemotherapy. However, chemotherapy RR was 65.5% (19/29, 95%CI 45.7–82.1). Conclusions VEC exceeded the pre-specified RR of 45% in children over three years with STR intracranial ependymoma. However, cases of inaccurate stratification at treating centres highlights the need for rapid central review. We also confirmed associations between 1q gain, hTERT expression and outcome.
Collapse
Affiliation(s)
- Timothy A. Ritzmann
- The University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | | | | | - Conor Mallucci
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - John-Paul Kilday
- Royal Manchester Children’s Hospital, Manchester, UK
- The University of Manchester, Manchester, UK
| | | | | | | | - Rob Dineen
- The University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Timothy Jaspan
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Kristian W Pajtler
- Hopp Children’s Cancer Center Heidelberg (KiTZ), Heidelberg, Germany
- Division of Pediatric Neurooncology, German Cancer Research Center (DKFZ) and German Cancer Consortium (DKTK), Heidelberg, Germany
| | - Thomas S Jacques
- UCL GOS Institute of Child Health, London, UK
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Simon M L Paine
- Nottingham University Hospitals NHS Trust, Nottingham, UK
- The University of Nottingham, Nottingham, UK
| | | | | | - Richard G Grundy
- The University of Nottingham, Nottingham, UK
- Nottingham University Hospitals NHS Trust, Nottingham, UK
| |
Collapse
|
22
|
Foster MT, Hennigan D, Grayston R, van Baarsen K, Sunderland G, Millward CP, Lalgudi Srinivasan H, Ferguson D, Totimeh T, Pizer B, Mallucci C. Reporting morbidity associated with pediatric brain tumor surgery: are the available scoring systems sufficient? J Neurosurg Pediatr 2021; 27:556-565. [PMID: 33636703 DOI: 10.3171/2020.9.peds20556] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/25/2020] [Accepted: 09/01/2020] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Complications in pediatric neurooncology surgery are seldom and inconsistently reported. This study quantifies surgical morbidity after pediatric brain tumor surgery from the last decade in a single center, using existing morbidity and outcome measures. METHODS The authors identified all pediatric patients undergoing surgery for an intracranial tumor in a single tertiary pediatric neurosurgery center between January 2008 and December 2018. Complications between postoperative days 0 and 30 that had been recorded prospectively were graded using appropriate existing morbidity scales, i.e., the Clavien-Dindo (CD), Landriel, and Drake scales. The result of surgery with respect to the predetermined surgical aim was also recorded. RESULTS There were 477 cases (364 craniotomies and 113 biopsies) performed on 335 patients (188 males, median age 9 years). The overall 30-day mortality rate was 1.26% (n = 6), and no deaths were a direct result of surgical complication. Morbidity on the CD scale was 0 in 55.14%, 1 in 10.69%, 2 in 18.66%, 3A in 1.47%, 3B in 11.74%, and 4 in 1.05% of cases. Morbidity using the Drake classification was observed in 139 cases (29.14%). Neurological deficit that remained at 30 days was noted in 8.39%; 78% of the returns to the operative theater were for CSF diversion. CONCLUSIONS To the authors' knowledge, this is the largest series presenting outcomes and morbidity from pediatric brain tumor surgery. The mortality rate and morbidity on the Drake classification were comparable to those of published series. An improved tool to quantify morbidity from pediatric neurooncology surgery is necessary.
Collapse
Affiliation(s)
- Mitchell T Foster
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool.,2Department of Neurosurgery, Walton Centre NHS Foundation Trust, Liverpool.,3Cancer Research UK Brain Tumour Centre of Excellence, The University of Edinburgh
| | - Dawn Hennigan
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool
| | - Rebecca Grayston
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool
| | - Kirsten van Baarsen
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool
| | - Geraint Sunderland
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool.,2Department of Neurosurgery, Walton Centre NHS Foundation Trust, Liverpool
| | - Christopher Paul Millward
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool.,2Department of Neurosurgery, Walton Centre NHS Foundation Trust, Liverpool
| | | | - Deborah Ferguson
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool.,4Department of Paediatric Neurosurgery, Royal Manchester Children's Hospital, Manchester; and
| | - Teddy Totimeh
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool
| | - Barry Pizer
- 5Department of Paediatric Oncology, Alder Hey Children's NHS Foundation Trust, Liverpool, United Kingdom
| | - Conor Mallucci
- 1Department of Paediatric Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool
| |
Collapse
|
23
|
Hall BJ, Gillespie CS, Sunderland GJ, Conroy EJ, Hennigan D, Jenkinson MD, Pettorini B, Mallucci C. Infant hydrocephalus: what valve first? Childs Nerv Syst 2021; 37:3485-3495. [PMID: 34402954 PMCID: PMC8578053 DOI: 10.1007/s00381-021-05326-1] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2021] [Accepted: 08/04/2021] [Indexed: 11/25/2022]
Abstract
PURPOSE To review the use of different valve types in infants with hydrocephalus, in doing so, determining whether an optimal valve choice exists for this patient cohort. METHODS We conducted (1) a literature review for all studies describing valve types used (programmable vs. non-programmable, valve size, pressure) in infants (≤ 2 years) with hydrocephalus, (2) a review of data from the pivotal BASICS trial for infant patients and (3) a separate, institutional cohort study from Alder Hey Children's Hospital NHS Foundation Trust. The primary outcome was any revision not due to infection. RESULTS The search identified 19 studies that were included in the review. Most did not identify a superior valve choice between programmable and non-programmable, small compared to ultra-small, and differential pressure compared to flow-regulating valves. Five studies investigated a single-valve type without a comparator group. The BASICS data identified 391 infants, with no statistically significant difference between gravitational and programmable subgroups. The institutional data from our tertiary referral centre did not reveal any significant difference in failure rate between valve subtypes. CONCLUSION Our review highlights the challenges of valve selection in infant hydrocephalus, reiterating that the concept of an optimal valve choice in this group remains a controversial one. While the infant-hydrocephalic population is at high risk of valve failure, heterogeneity and a lack of direct comparison between valves in the literature limit our ability to draw meaningful conclusions. Data that does exist suggests at present that there is no difference in non-infective failure rate are increasing in number, with the British valve subtypes in infant hydrocephalus, supported by both the randomised trial and institutional data in this study.
Collapse
Affiliation(s)
- Benjamin J Hall
- Department of Neurosurgery, Alder Hey Children's NHS Trust, Liverpool, UK
- Aintree University Hospitals NHS Foundation Trust, Liverpool, UK
| | - Conor S Gillespie
- Department of Neurosurgery, Alder Hey Children's NHS Trust, Liverpool, UK.
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Biosciences Building, Crown Street, Liverpool, L69 7BE, UK.
| | - Geraint J Sunderland
- Department of Neurosurgery, Alder Hey Children's NHS Trust, Liverpool, UK
- Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
| | - Elizabeth J Conroy
- Liverpool Clinical Trials Centre, University of Liverpool, Liverpool, UK
| | - Dawn Hennigan
- Department of Neurosurgery, Alder Hey Children's NHS Trust, Liverpool, UK
| | - Michael D Jenkinson
- Institute of Systems, Molecular and Integrative Biology, University of Liverpool, Biosciences Building, Crown Street, Liverpool, L69 7BE, UK
- Institute of Infection Veterinary and Ecological Sciences, University of Liverpool, Liverpool, UK
| | | | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Trust, Liverpool, UK
| |
Collapse
|
24
|
Hartley H, Lane S, Pizer B, Bunn L, Carter B, Cassidy E, Mallucci C, Kumar R. Ataxia and mobility in children following surgical resection of posterior fossa tumour: A longitudinal cohort study. Childs Nerv Syst 2021; 37:2831-2838. [PMID: 34232381 PMCID: PMC8423635 DOI: 10.1007/s00381-021-05246-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/19/2020] [Accepted: 04/23/2021] [Indexed: 11/24/2022]
Abstract
PURPOSE To report the course of ataxia in children up to 2 years post-operatively, following surgical resection of a posterior fossa tumour (PFT). METHODS Thirty-five children, (median age 9 years, range 4-15) having resection of PFT, were assessed using the Scale for the Assessment and Rating of Ataxia (SARA), Brief Ataxia Rating Scale (BARS) and the mobility domain of the Paediatric Evaluation of Disability Index (PEDI-m) at initial post-operative period (baseline), 3 months, 1 year and 2 years post-operatively. RESULTS Baseline median scores of the SARA and BARS were 8.5 (range 0-35.5), and 7 (0-25) respectively. Ataxia improved at 3 months (median SARA and BARS reduction 3.5 and 4, respectively). Additional gradual improvements in SARA were recorded at 1 (median reduction 2) and 2 years post-operatively (median reduction 0.5). Median baseline PEDI-m was 54.75 (range 15.2-100) with improvement at 3 months (median increase 36.95) and small improvement at 1 year (median increase 2.5) and 2 years (median increase 5.8). Children with medulloblastoma and midline tumours (median baseline SARA 10 and 11, respectively) demonstrated more severe ataxia than children with low-grade gliomas and unilateral tumours (median baseline SARA 7.5 and 6.5, respectively). CONCLUSION The largest improvement in ataxia scores and functional mobility scores is demonstrated within the first 3 months post-operatively, but ongoing gradual improvement is observed at 2 years. Children with medulloblastoma and midline tumour demonstrated higher ataxia scores long term.
Collapse
Affiliation(s)
- H Hartley
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - S Lane
- University of Liverpool, Liverpool, UK
| | - B Pizer
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - L Bunn
- University of Plymouth, Plymouth, UK
| | - B Carter
- Edge Hill University, Ormskirk, UK.
| | | | - C Mallucci
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - R Kumar
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
25
|
Chari A, Mallucci C, Whitelaw A, Aquilina K. Intraventricular haemorrhage and posthaemorrhagic ventricular dilatation: moving beyond CSF diversion. Childs Nerv Syst 2021; 37:3375-3383. [PMID: 33993367 PMCID: PMC8578081 DOI: 10.1007/s00381-021-05206-8] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2021] [Accepted: 05/04/2021] [Indexed: 11/28/2022]
Abstract
Advances in medical care have led to more premature babies surviving the neonatal period. In these babies, germinal matrix haemorrhage (GMH), intraventricular haemorrhage (IVH) and posthaemorrhagic ventricular dilatation (PHVD) are the most important determinants of long-term cognitive and developmental outcomes. In this review, we discuss current neurosurgical management of IVH and PHVD, including the importance of early diagnosis of PHVD, thresholds for intervention, options for early management through the use of temporising measures and subsequent definitive CSF diversion. We also discuss treatment options for the evolving paradigm to manage intraventricular blood and its breakdown products. We review the evidence for techniques such as drainage, irrigation, fibrinolytic therapy (DRIFT) and neuroendoscopic lavage in the context of optimising cognitive, neurodevelopmental and quality of life outcomes in these premature infants.
Collapse
Affiliation(s)
- Aswin Chari
- Department of Neurosurgery, Great Ormond Street Hospital, London, UK ,Developmental Neurosciences, Great Ormond Street Institute of Child Health, University College London, London, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children’s Hospital, Liverpool, UK
| | - Andrew Whitelaw
- Neonatal Neuroscience, Translational Health Sciences, University of Bristol, Bristol, UK
| | - Kristian Aquilina
- Department of Neurosurgery, Great Ormond Street Hospital, London, UK. .,Developmental Neurosciences, Great Ormond Street Institute of Child Health, University College London, London, UK.
| |
Collapse
|
26
|
Hall BJ, S. Gillespie C, Hennigan D, Bagga V, Mallucci C, Pettorini B. Efficacy and safety of the Miethke programmable differential pressure valve (proGAV®2.0): a single-centre retrospective analysis. Childs Nerv Syst 2021; 37:2605-2612. [PMID: 34021371 PMCID: PMC8342385 DOI: 10.1007/s00381-021-05162-3] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/01/2021] [Accepted: 04/09/2021] [Indexed: 11/28/2022]
Abstract
PURPOSE Achieving decompression without CSF over-drainage remains a challenge in hydrocephalus. Differential pressure valves are a popular treatment modality, with evidence suggesting that incorporation of gravitational units helps minimise over-drainage. This study seeks to describe the utility of the proGAV®2.0 programmable valve in a paediatric population. METHODS Clinical records and imaging of all patients fitted with proGAV®2.0 valves and Miethke fixed-pressure valves between 2014 and 2019 at our tertiary centre were analysed. Patient demographics, indication for shunt and valve insertion/revision and time to shunt/valve revision were collected. Ventricular linear metrics (fronto-occipital horn ratio (FOHR) and fronto-occipital horn width ratio (FOHWR)) were collected pre- and post-valve insertion. Microsoft Excel and SPSS v24 were used for data collection and statistical analysis. RESULTS Eighty-eight proGAV®2.0 valves were inserted in a population of 77 patients (n = 45 males (58%), mean age 5.1 years (IQR: 0.4-11.0 years)). A total of 102 Miethke fixed-pressure valves were inserted over the same time period. Median follow-up was 17.5 months (1.0-47.3). One (1.1%) proGAV®2.0 was revised due to over-drainage, compared to 2 (1.9%) fixed-pressure valves (p > 0.05). ProGAV®2.0 insertion resulted in a significant decrease in the mean number of revisions per patient per year (1.77 vs 0.25; p = 0.01). Overall shunt system survival with the proGAV®2.0 was 80.4% at 12 months, and mean time to revision was 37.1 months, compared to 31.0 months (95%CI: 25.7-36.3) and 58.3% in fixed-pressure valves (p < 0.01). Significant decreases were seen following proGAV®2.0 insertion in both FOHR and FOHWR, by 0.014 (95%CI: 0.006-0.023, p = 0.002) and 0.037 (95%CI: 0.005-0.069, p = 0.024) respectively. CONCLUSION The proGAV®2.0 provides effective decompression of hydrocephalic patients, significantly reduces the number of valve revisions per patient and had a significantly greater mean time to revision than fixed-pressure valves.
Collapse
Affiliation(s)
- Benjamin J. Hall
- Aintree University Hospital, Liverpool University Hospitals NHS Foundation Trust, Liverpool, L9 7AL UK
| | | | - Dawn Hennigan
- Alder Hey Children’s Hospital, NHS Foundation Trust, Liverpool, L14 5AB UK
| | - Veejay Bagga
- Alder Hey Children’s Hospital, NHS Foundation Trust, Liverpool, L14 5AB UK
| | - Conor Mallucci
- Alder Hey Children’s Hospital, NHS Foundation Trust, Liverpool, L14 5AB UK
| | | |
Collapse
|
27
|
Foster M, Hennigan D, Greystone R, van Baarsen K, Sunderland G, Millward C, Srinivasan H, Ferguson D, Totimeh T, Pizer B, Mallucci C. SURG-12. PAEDIATRIC BRAIN TUMOUR SURGERY: HOW CAN WE REPORT OUR SURGICAL OUTCOMES AND OPERATIVE MORBIDITY? Neuro Oncol 2020. [PMCID: PMC7715701 DOI: 10.1093/neuonc/noaa222.808] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/03/2022] Open
Abstract
OBJECTIVE Our objective was to quantify resection outcomes and operative morbidity in paediatric brain tumour surgery using existing scales, assessing their applicability. METHODS We investigated morbidity using the Clavien-Dindo (CD) scale and the Drake classification. All paediatric patients receiving a biopsy or craniotomy for an intracranial tumour in a single tertiary paediatric neurosurgery centre between January 2008 and December 2018 were studied. Complications up to day 30 post op were graded. RESULTS There were 459 operations: 92 biopsies and 367 craniotomies comprising 166 infratentorial and 292 supratentorial tumours. Median age was 9 years (56% male). The surgical goal was achieved or exceeded in 94% of cases. Thirty-day mortality was 1.31% with all deaths related to disease and none to surgical complications. The overall CD score was 1 in 10.9% of cases, 2 in 18.9%, 3A in 1.7%, 3B in 11.8%, and 4 in 1.1%. There was no operative morbidity in 54% of cases. Using the Drake classification, meningitis was seen in 3.92% of cases, seizures in 3.92%, neurological deficit (that persisted at 30 days) in 8.5%, CSF leak in 5.01%, wound infection in 1.96%, haemorrhage 1.75 %, shunt infection in 1.53%, shunt block in 0.65%, medical complications in 2.4%, and others in 3.05%. CONCLUSIONS This is the largest series presenting morbidity from paediatric brain tumour surgery, and the first to validate the CD scale. Our morbidity on the Drake scale was comparable with other series. There is a need to develop improved tools to quantify morbidity in this high-risk specialty.
Collapse
Affiliation(s)
- Mitchell Foster
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | - Dawn Hennigan
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | - Rebecca Greystone
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | | | | | | | | | - Deborah Ferguson
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | | | - Barry Pizer
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | - Conor Mallucci
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| |
Collapse
|
28
|
Macarthur DC, Mallucci C, Kamaly-Asl I, Goodden J, Storer LCD, Chapman RJ, Kilday JP, English M, Jaspan T, Chattopadhyay A, Dineen RA, Avula S, Stivaros S, Grundy R. EPEN-24. SIOP EPENDYMOMA II: CENTRAL EPENDYMOMA MANAGEMENT ADVISORY GROUP – THE UK EXPERIENCE. Neuro Oncol 2020. [PMCID: PMC7715772 DOI: 10.1093/neuonc/noaa222.161] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Paediatric Ependymoma is the second most common malignant brain tumour of childhood with approximately 50% of cases recurring. It has been described as a “surgical” disease since patients who have undergone a gross total surgical resection (GTR) have a better prognosis than those who have a subtotal resection (STR). Analysis of the UKCCSG/SIOP 1992 04 clinical trial has shown that only 49% of cases had a GTR, with 5-year survival rates for STR of 22–47% and GTR of 67–80%. As part of the SIOP II Ependymoma trial the UK established a panel of experts in the treatment of Ependymoma from Neuro-oncology, Neuro-radiology and Neuro-surgery. Meeting weekly, cases are discussed to provide a consensus on radiological review, ensuring central pathological review, trial stratification and whether further surgery should be advocated on any particular case. Evaluation of the first 68 UK patients has shown a GTR in 47/68 (69%) of patients and STR in 21/68 (31%) of patients. Following discussion at EMAG it was felt that 9/21 (43%) STR patients could be offered early second look surgery. Following this 2nd look surgery the number of cases with a GTR increased to 56/68 (82%). There has been a clear increase in the number of patients for whom a GTR has been achieved following discussion at EMAG and prior to them moving forwards with their oncological treatment. This can only have beneficial effects in decreasing their risk of tumour recurrence or CSF dissemination and also in reducing the target volume for radiotherapy.
Collapse
Affiliation(s)
- Donald C Macarthur
- Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom
- Birmingham Children’s Hospital, Birmingham, West Midlands, United Kingdom
| | - Conor Mallucci
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | - Ian Kamaly-Asl
- Royal Manchester Children’s Hospital, Manchester, Lancashire, United Kingdom
| | - John Goodden
- Leeds Teaching Hospitals, Leeds, Yorkshire, United Kingdom
| | - Lisa C D Storer
- School of Medicine, University of Nottingham, Nottinghamshire, United Kingdom
| | - Rebecca J Chapman
- School of Medicine, University of Nottingham, Nottinghamshire, United Kingdom
| | - J-P Kilday
- Royal Manchester Children’s Hospital, Manchester, Lancashire, United Kingdom
| | - Martin English
- Birmingham Children’s Hospital, Birmingham, West Midlands, United Kingdom
| | - Tim Jaspan
- Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom
| | | | - Rob A Dineen
- Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom
- Birmingham Children’s Hospital, Birmingham, West Midlands, United Kingdom
| | - Shivaram Avula
- Alder Hey Children’s Hospital, Liverpool, Merseyside, United Kingdom
| | - Stavros Stivaros
- Royal Manchester Children’s Hospital, Manchester, Lancashire, United Kingdom
| | - Richard Grundy
- Nottingham University Hospitals, Nottingham, Nottinghamshire, United Kingdom
- Birmingham Children’s Hospital, Birmingham, West Midlands, United Kingdom
| |
Collapse
|
29
|
Grønbæk JK, Wibroe M, Toescu S, Grillner P, Mallucci C, Molinari E, Solem K, Westerholm-Ormio M, Kiudeliene R, Mudra K, Hauser P, van Baarsen K, Hoving E, Zipfel J, Nysom K, Schmiegelow K, Sehested A, Juhler M, Mathiasen R. QOL-59. CEREBELLAR MUTISM SYNDROME AND THE SURGICAL RISK FACTORS: A PROSPECTIVE MULTICENTRE STUDY OF 500 PATIENTS UNDERGOING TUMOUR SURGERY IN THE POSTERIOR FOSSA. Neuro Oncol 2020. [PMCID: PMC7715299 DOI: 10.1093/neuonc/noaa222.712] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
OBJECTIVE Cerebellar mutism syndrome (CMS) is a severe neurological complication of tumour surgery in the posterior fossa in childhood. The incidence is reported between 8 and 39%, where CMS sets in within days of surgery and resolves within months, yet long-term sequelae are seen in most patients. This prospective cohort study investigates the course of CMS and the surgical cause of the syndrome. POPULATION AND METHODS We included 500 children with a tumour in the posterior fossa with planned surgery or open biopsy. Enrolment was conducted between 2014 and 2020 in 26 centres in ten European countries. Speech, neurological symptoms and surgical procedure were registered in predefined standardized forms pre-operatively and at three post-operative follow-ups within one year. PRELIMINARY RESULTS A total of 426 children underwent primary surgery and were eligible for analyses. CMS occurred in 56 patients (13.1%) one day (median; IQR: 0–2 days) after surgery and resolved within 38 days (median; IQR: 4–52 days). Another 58 patients (13.6%) had less severe speech impairment. Mutism was associated with lower age (OR: 0.91 [95%CI: 0.85;0.98, p=0.014]), medulloblastoma (OR: 2.5 [95%CI: 1.4;4.7, p=0.0036]) and ATRT (OR: 12.9 [95%CI: 3.4;51.9, p=0.00018]) and tumour location in the fourth ventricle (OR: 4.0 [95%CI: 2.3;7.2, p<0.0001]). Preliminary multivariate analyses revealed no significant association between mutism and surgical access. CONCLUSION CMS is a common complication predominantly seen in younger children after tumour surgery for a medulloblastoma or ATRT in the fourth ventricle. The incidence is not related to the surgical access in this study population.
Collapse
Affiliation(s)
- Jonathan Kjær Grønbæk
- Department of Neurosurgery, The University Hospital Rigshospitalet, Copenhagen, Denmark
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Morten Wibroe
- Department of Neurosurgery, The University Hospital Rigshospitalet, Copenhagen, Denmark
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Sebastian Toescu
- Developmental Imaging and Biophysics Section, UCL-GOS Institute of Child Health, London, UK
- Department of Neurosurgery, Great Ormond Street Hospital for Children, London, UK
| | - Pernilla Grillner
- Pediatric Oncology, Karolinska University Hospital, Stockholm, Sweden
| | - Conor Mallucci
- Department of Paediatric Neurosurgery, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - Emanuela Molinari
- Department of Neurology, The Queen Elizabeth University Hospital, University of Glasgow, Glasgow, UK
| | - Kristin Solem
- Department of Pediatrics, St Olavs Hospital, Trondheim, Norway
| | | | - Rosita Kiudeliene
- Center of Pediatric Oncology and Hematology at Pediatric Department and Hospital of Kauno Klinikos, Lithuanian University of Health Sciences, Kaunas, Lithuania
| | - Katalin Mudra
- 2nd Dept. of Pediatrics, Semmelweis University, Budapest, Hungary
| | - Peter Hauser
- Pediatric Oncology and Transplantation Unit, Velkey László Child’s Health Center, Borsod-Abaúj-Zemplén County University Teaching Hospital, Miskolc, Hungary
| | | | - Eelco Hoving
- Princess Máxima Center for Pediatric Oncology, Utrecht, The Netherlands
| | - Julian Zipfel
- Department of Neurosurgery, Pediatric Neurosurgery, University Hospital Tuebingen, Tuebingen, Germany
| | - Karsten Nysom
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Kjeld Schmiegelow
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
- Institute of Clinical Medicine, Faculty of Medicine, University of Copenhagen, Copenhagen, Denmark
| | - Astrid Sehested
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| | - Marianne Juhler
- Department of Neurosurgery, The University Hospital Rigshospitalet, Copenhagen, Denmark
- Department of Neurosurgery, Aarhus University Hospital, Aarhus, Denmark
| | - René Mathiasen
- Department of Paediatrics and Adolescent Medicine, The University Hospital Rigshospitalet, Copenhagen, Denmark
| |
Collapse
|
30
|
Shabo E, Czech T, Nicholoson JC, Mallucci C, Sarikaya-Seiwert S, Guerini-Rousseau L, Piatelli G, Murray MC, Faure-Conter C, Calaminus G. GCT-49. EVALUATION OF THE PERIOPERATIVE AND POSTOPERATIVE COURSE OF SURGERY OF PINEAL GERMINOMA ACCORDING TO THE SIOP CNS GCT 96 TRIAL. Neuro Oncol 2020. [PMCID: PMC7715123 DOI: 10.1093/neuonc/noaa222.267] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
Abstract
INTRODUCTION CNS germinoma, being marker-negative, are diagnosed by surgical biopsy. Here we evaluate the perioperative status and postoperative complications of patients with pineal germinoma who underwent a primary biopsy or resection, treated according to SIOP CNS GCT 96. METHODS 235 patients with histologically confirmed germinoma were registered, of which 113 were pineal: 55 were biopsied and 58 underwent primary resection. Initial symptoms, tumour size, complications and neurological status were assessed. 111 patients were evaluable. RESULTS Pure germinoma was present in 101 patients; 10 had additional teratoma components. The main clinical symptoms at diagnosis were headache (n=98), hydrocephalus (n=93), double vision (n=62), Parinaud syndrome (n=57) and papilloedema (n=44). Tumour size was documented in 81 patients (<2cm, n=14; 2-3cm, n=35; ≥3cm, n=32). 17 patients underwent primary total resection, 14 subtotal resection >50%, 26 subtotal resection <50%, 39 stereotactic biopsy, 11 endoscopic biopsy, 2 open biopsy and 2 not documented. The postoperative neurological status after resection was improved in 23 patients, unchanged in 27, deteriorated in 6 and not documented in one. Clinical status after biopsy improved in 26 patients, was unchanged in 15, deteriorated in 2 and not documented in 11. Postoperatively, 16/57 patients after resection and 5/54 after biopsy developed complications (Parinaud syndrome, double vision and hydrocephalus). CONCLUSION Although surgical techniques have improved within recent decades, these results support the practice of biopsy over resection for histological confirmation of germinoma arising at the pineal site. Supported in part by German Cancer Aid.
Collapse
Affiliation(s)
- Ehab Shabo
- Department of Neurosurgery, University Hospital, Bonn, Germany
| | - Thomas Czech
- Department of Neurosurgery, University Hospital, Vienna, Austria
| | - James C Nicholoson
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridge, United Kingdom
| | - Conor Mallucci
- Alder Hey Children’s Hospital, Eaton Road, Liverpool, United Kingdom
| | | | - Lea Guerini-Rousseau
- Department of Pediatric and Adolescents Oncology, Institut Gustave Roussy Cancer Center, Paris-Saclay University, Villejuif, France
| | - Gianluca Piatelli
- Neuro-Oncology Unit, Department of Pediatric Hematology and Oncology, G, Gaslini Children’s Hospital, Genova, Genova, Italy
| | - Matthew C Murray
- Department of Paediatric Haematology and Oncology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridge, United Kingdom
| | - Cecile Faure-Conter
- Department of Paediatric Haematology and Oncology, Institute of Paediatric Haematology and Oncology (IHOPe), Lyon, France
| | - Gabriele Calaminus
- Department of Paediatric Haematology and Oncology University Hospital, Bonn, Germany
| |
Collapse
|
31
|
Sokratous G, Hadfield O, Van Tonder L, Hennigan D, Ellenbogen J, Pettorini B, Mallucci C. Management of paediatric hydrocephalous with Miethke fixed pressure gravitational valves. The Alder Hey Children's Hospital experience. Childs Nerv Syst 2020; 36:2021-2025. [PMID: 32020268 DOI: 10.1007/s00381-020-04520-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/16/2019] [Accepted: 01/24/2020] [Indexed: 11/30/2022]
Abstract
OBJECTIVE The management of paediatric hydrocephalous remains challenging with the complication and revision rates being consistent in the literature. We hypothesise that the use of a fixed pressure gravitational valve for all de novo shunt insertions decreases the rate of functional revisions and that by implementing the routine use of gravitational valves in children, we would see a reduction in over-drainage and slit ventricle syndrome. METHODS Retrospective data collection in a single centre, between February 2010 and August 2018. All patients undergoing fixed pressure gravitational Miethke valve insertion were included. We collected data on patients' demographics, reason for shunt insertion, type of valve and time to and reason for first revision. Data analysis was done with SPSS. RESULTS A total of 235 patients were included in our study (124 males, 111 females), aged from 0 to 18.6 years (median 0.28). A total of 99 shunt revisions were documented, 30 of which secondary to ventricular catheter malfunction and 28 secondary to infection. The overall mechanical valve survival rates were 88.5%, 86.4% and 85.5% at 1, 2 and 5 years, respectively. Shunt revision due to over-drainage was documented in only 3 cases (1.3%). CONCLUSION Our results are in agreement with existing literature regarding shunt failures secondary to all extrinsic factors to the valve (infection and mechanical failure). We have shown that the use of a Miethke fixed pressure valve for all de novo shunt insertions in paediatric hydrocephalus decreases the need for functional revisions with valve survival rates being superior to the ones described for other types.
Collapse
Affiliation(s)
- Giannis Sokratous
- Department of Neurosurgery, Alder Hey Children's Hospital, Liverpool, UK.
| | | | - Libby Van Tonder
- Department of Neurosurgery, Alder Hey Children's Hospital, Liverpool, UK
| | - Dawn Hennigan
- Department of Neurosurgery, Alder Hey Children's Hospital, Liverpool, UK
| | | | | | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's Hospital, Liverpool, UK
| |
Collapse
|
32
|
Coulter IC, Kulkarni AV, Sgouros S, Constantini S, Constantini S, Sgouros S, Kulkarni AV, Leitner Y, Kestle JR, Cochrane DD, Choux M, Gjerris F, Sherer A, Akalan N, Bilginer B, Navarro R, Vujotic L, Haberl H, Thomale UW, Zúccaro G, Jaimovitch R, Frim D, Loftis L, Swift DM, Robertson B, Gargan L, Bognár L, Novák L, Cseke G, Cama A, Ravegnani GM, Preuß M, Schroeder HW, Fritsch M, Baldauf J, Mandera M, Luszawski J, Skorupka P, Mallucci C, Williams D, Zakrzewski K, Nowoslawska E, Srivastava C, Mahapatra AK, Kumar R, Sahu RN, Melikian AG, Korshunov A, Galstyan A, Suri A, Gupta D, Grotenhuis JA, van Lindert EJ, da Costa Val JA, Di Rocco C, Tamburrini G, Zymberg ST, Cavalheiro S, Jie M, Feng J, Friedman O, Rajmohamed N, Roszkowski M, Barszcz S, Jallo G, Pincus DW, Richter B, Mehdorn HM, Schultka S, de Ribaupierre S, Thompson D, Gatscher S, Wagner W, Koch D, Cipri S, Zaccone C, McDonald P. Cranial and ventricular size following shunting or endoscopic third ventriculostomy (ETV) in infants with aqueductal stenosis: further insights from the International Infant Hydrocephalus Study (IIHS). Childs Nerv Syst 2020; 36:1407-1414. [PMID: 31965292 DOI: 10.1007/s00381-020-04503-y] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/01/2019] [Accepted: 01/02/2020] [Indexed: 11/24/2022]
Abstract
PURPOSE The craniometrics of head circumference (HC) and ventricular size are part of the clinical assessment of infants with hydrocephalus and are often utilized in conjunction with other clinical and radiological parameters to determine the success of treatment. We aimed to assess the effect of endoscopic third ventriculostomy (ETV) and shunting on craniometric measurements during the follow-up of a cohort of infants with symptomatic triventricular hydrocephalus secondary to aqueductal stenosis. METHODS We performed a post hoc analysis of data from the International Infant Hydrocephalus Study (IIHS)-a prospective, multicenter study of infants (< 24 months old) with hydrocephalus from aqueductal stenosis who were treated with either an ETV or shunt. During various stages of a 5-year follow-up period, the following craniometrics were measured: HC, HC centile, HC z-score, and frontal-occipital horn ratio (FOR). Data were compared in an analysis of covariance, adjusting for baseline variables including age at surgery and sex. RESULTS Of 158 enrolled patients, 115 underwent an ETV, while 43 received a shunt. Both procedures led to improvements in the mean HC centile position and z-score, a trend which continued until the 5-year assessment point. A similar trend was noted for FOR which was measured at 12 months and 3 years following initial treatment. Although the values were consistently higher for ETV compared with shunt, the differences in HC value, centile, and z-score were not significant. ETV was associated with a significantly higher FOR compared with shunting at 12 months (0.52 vs 0.44; p = 0.002) and 3 years (0.46 vs 0.38; p = 0.03) of follow-up. CONCLUSION ETV and shunting led to improvements in HC centile, z-score, and FOR measurements during long-term follow-up of infants with hydrocephalus secondary to aqueductal stenosis. Head size did not significantly differ between the treatment groups during follow-up, however ventricle size was greater in those undergoing ETV when measured at 1 and 3 years following treatment.
Collapse
Affiliation(s)
- Ian C Coulter
- The Hospital for Sick Children, University of Toronto, 555 University Avenue, Suite 1503, Toronto, Ontario, M5G 1X8, Canada
| | - Abhaya V Kulkarni
- The Hospital for Sick Children, University of Toronto, 555 University Avenue, Suite 1503, Toronto, Ontario, M5G 1X8, Canada.
| | - Spyros Sgouros
- Department of Pediatric Neurosurgery, Mitera Children's Hospital, Athens, Greece.,University of Athens Medical School, Athens, Greece
| | - Shlomi Constantini
- Department of Pediatric Neurosurgery, Dana Children's Hospital, Tel Aviv Sourasky Medical Center, Tel Aviv University, Tel Aviv, Israel
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
33
|
Sethi A, Didi M, Dharmaraj P, Ramakrishnan R, Senniappan S, Das U, Avula S, Sinha A, Mallucci C, Weerasinghe K, Daousi C, Gilkes C, Thorp N, Blair J. Obesity is common at diagnosis of childhood pituitary adenoma and may persist following successful treatment. Clin Endocrinol (Oxf) 2020; 92:323-330. [PMID: 31876026 DOI: 10.1111/cen.14146] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/31/2019] [Revised: 12/15/2019] [Accepted: 12/19/2019] [Indexed: 11/27/2022]
Abstract
OBJECTIVE There is a paucity of data describing long-term outcomes of paediatric patients with pituitary adenoma. In this report, we describe clinical features, treatment and outcomes of a paediatric cohort. DESIGN Retrospective cohort study. PATIENTS Twenty-four white Caucasian patients aged <16 years from a single tertiary care centre in the United Kingdom at diagnosis followed for (median, range) 3.3, 0.7-8.4 years. MEASUREMENTS Clinical and radiological data at diagnosis and follow-up. RESULTS Thirteen patients had prolactinomas (54.1%, age: 15.2 years, 13.2-15.8 years; all females), including ten macroadenomas (11.0-35.0 mm). Patients presented with menstrual disorders (91%), headache (46%), galactorrhoea (46%) and obesity (body mass index [BMI] SDS > 2): (38%). Ten patients with prolactinoma were treated with dopamine agonist alone, 3 also required surgery and 2 patients, cabergoline, surgery plus radiotherapy. Five patients had Cushing's disease (20.8%, age: 14.0, 4.0-15.7 years; 2 female), including one macroadenoma (24 mm). Patients presented with obesity (100%), short stature (60%) and headache (40%). Transsphenoidal resection resulted in biochemical cure (09.00 cortisol < 50 nmol/L). Two patients relapsed 3- and 6 years following surgery, requiring radiotherapy. One patient also required bilateral adrenalectomy. Six patients had nonfunctioning pituitary adenoma (25.0%, age: 15.8, 12.5-16.0 years; 2 female), including two macroadenomas (20.0-53.0 mm). Patients presented with obesity (67%), visual field defects (50%) and headache (50%). Four required surgical resections; two recurred following surgery and required radiotherapy. On latest follow-up; 13 (54.1%) patients were obese (BMI 3.09 SDS; range: 2.05-3.73 SDS). CONCLUSION Obesity is common at diagnosis of pituitary adenoma in childhood and may persist despite successful treatment. Adenomas were larger, more resistant to treatment, and more likely to recur than in adult populations.
Collapse
Affiliation(s)
- Aashish Sethi
- Department of Endocrinology, Alder Hey Children's Hospital, Liverpool, UK
| | - Mohammed Didi
- Department of Endocrinology, Alder Hey Children's Hospital, Liverpool, UK
| | - Poonam Dharmaraj
- Department of Endocrinology, Alder Hey Children's Hospital, Liverpool, UK
| | | | - Senthil Senniappan
- Department of Endocrinology, Alder Hey Children's Hospital, Liverpool, UK
| | - Urmi Das
- Department of Endocrinology, Alder Hey Children's Hospital, Liverpool, UK
| | - Shivaram Avula
- Department of Radiology, Alder Hey Children's Hospital, Liverpool, UK
| | - Ajay Sinha
- Department of Neurosurgery, Alder Hey Children's Hospital, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's Hospital, Liverpool, UK
| | | | | | - Catherine Gilkes
- Department of Endocrinology, Aintree University Hospital, Liverpool, UK
| | - Nicola Thorp
- Department of Clinical Oncology, Clatterbridge Cancer Centre, Bebington, UK
| | - Joanne Blair
- Department of Endocrinology, Alder Hey Children's Hospital, Liverpool, UK
| |
Collapse
|
34
|
Tejada S, Aquilina K, Goodden J, Pettorini B, Mallucci C, van Veelen ML, Thomale UW. Biopsy in diffuse pontine gliomas: expert neurosurgeon opinion-a survey from the SIOPE brain tumor group. Childs Nerv Syst 2020; 36:705-711. [PMID: 32020269 DOI: 10.1007/s00381-020-04523-8] [Citation(s) in RCA: 13] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/29/2019] [Accepted: 01/25/2020] [Indexed: 12/20/2022]
Abstract
INTRODUCTION The prognosis of diffuse intrinsic pontine glioma (DIPG) is poor. The role of biopsy in DIPG remains controversial since the diagnosis may be established with imaging alone. Recent advances in understanding molecular biology and targeting of brain tumors have created a renewed interest in biopsy for DIPG. The Neurosurgery Working Group (NWG) of the SIOP-Europe Brain Tumor Group (BTG) undertook a survey among international pediatric neurosurgeons to define their current perceptions and practice regarding DIPG biopsy. METHODS The NWG developed a 20-question survey which was emailed to neurosurgeons in the International Society for Pediatric Neurosurgery (ISPN). The questionnaire included questions on diagnosis, indications, and techniques for biopsy, clinical trials, and healthcare infrastructure. RESULTS The survey was sent to 202 neurosurgeons and 73 (36%) responded. Consensus of > 75% agreement was reached for 12/20 questions, which included (1) radiological diagnosis of DIPG is sufficient outside a trial, (2) clinical trial-based DIPG biopsy is justified if molecular targets are investigated and may be used for treatment, and (3) morbidity/mortality data must be collected to define the risk:benefit ratio. The remaining 8/20 questions proved controversial and failed to reach consensus. CONCLUSIONS Routine DIPG biopsy continues to be debated. Most neurosurgeons agreed that DIPG biopsy within a clinical trial should be supported, with the aims of defining the procedure risks, improving understanding of tumor biology, and evaluating new treatment targets. Careful family counseling and consent remain important.
Collapse
Affiliation(s)
- Sonia Tejada
- Department of Neurosurgery, IIS-Fundación Jimenez Diaz-UAM, Hospital Fundación Jiménez Díaz, Grupo Quirón, Madrid, Spain.
| | | | - John Goodden
- Neurosurgery Department, Leeds General Infirmary, Leeds, UK
| | | | - Conor Mallucci
- Neurosurgery Department, Alder Hey Children's NHS Foundation, Liverpool, UK
| | | | - Ulrich-W Thomale
- Department of Pediatric Neurosurgery, Charité Universitätsmedizin, Berlin, Germany
| |
Collapse
|
35
|
Richards A, Ved R, Murphy C, Hennigan D, Kilday JP, Kamaly-Asl I, Mallucci C, Bhatti I, Patel C, Leach P. Outcomes with respect to extent of surgical resection for pediatric atypical teratoid rhabdoid tumors. Childs Nerv Syst 2020; 36:713-719. [PMID: 31889208 DOI: 10.1007/s00381-019-04478-5] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/16/2019] [Revised: 10/16/2019] [Accepted: 12/17/2019] [Indexed: 12/30/2022]
Abstract
PURPOSE To evaluate overall survival for atypical teratoid rhabdoid tumors (ATRTs) in relation to extent of surgical resection. METHODS The neurosurgical tumor databases from three UK Pediatric centers (University Hospital of Wales, Alder Hey and Royal Manchester Children's Hospital) were analyzed. Patients with a diagnosis of ATRT were identified between 2000 and 2018. Data was collected regarding demographics, extent of resection, complications, and overall survival. RESULTS Twenty-four patients diagnosed with ATRT underwent thirty-eight operations. The age range was 20 days to 147 months (median 17.5 months). The most common location for the tumor was the posterior fossa (nine patients; 38%). Six patients (25%) underwent a complete total resection (CTR), seven (29%) underwent a near total resection (NTR), eight (33.3%) underwent a subtotal resection (STR), and three patients (12.5%) had biopsy only. Two-thirds of patients who underwent a CTR are still alive, as of March 2019, compared to 29% in the NTR and 12.5% in the STR groups. Out of the thirty-eight operations, there were a total of twenty-two complications, of which the most common was pseudomeningocele (27%). The extent of surgical resection (p = 0.021), age at surgery (p = 0.00015), and the presence of metastases at diagnosis (0.015) significantly affected overall survival. CONCLUSIONS Although these patients are a highly vulnerable group, maximal resection is recommended where possible, for the best chance of long-term survival. However, near total resections are likely beneficial when compared with subtotal resections and biopsy alone. Maximal surgical resection should be combined with adjuvant therapies for the best long-term outcomes.
Collapse
Affiliation(s)
- Alexandra Richards
- Department of Pediatric Neurosurgery, University Hospital of Wales, Cardiff, CF14 4XW, UK.
| | - Ronak Ved
- Department of Pediatric Neurosurgery, University Hospital of Wales, Cardiff, CF14 4XW, UK
| | - Christopher Murphy
- Department of Pediatric Neurosurgery, Royal Manchester Children's Hospital, Manchester, M13 9WL, UK
| | - Dawn Hennigan
- Department of Pediatric Neurosurgery, Alder Hey Children's Hospital, Liverpool, L14 5AB, UK
| | - John-Paul Kilday
- Department of Pediatric Neuro-Oncology, Children's Brain Tumor Research Network, Royal Manchester Children's Hospital, Manchester, M13 9WL, UK
| | - Ian Kamaly-Asl
- Department of Pediatric Neurosurgery, Royal Manchester Children's Hospital, Manchester, M13 9WL, UK
| | - Conor Mallucci
- Department of Pediatric Neurosurgery, Alder Hey Children's Hospital, Liverpool, L14 5AB, UK
| | - Imran Bhatti
- Department of Pediatric Neurosurgery, University Hospital of Wales, Cardiff, CF14 4XW, UK
| | - Chirag Patel
- Department of Pediatric Neurosurgery, University Hospital of Wales, Cardiff, CF14 4XW, UK
| | - Paul Leach
- Department of Pediatric Neurosurgery, University Hospital of Wales, Cardiff, CF14 4XW, UK
| |
Collapse
|
36
|
Srinivasan HL, Foster MT, van Baarsen K, Hennigan D, Pettorini B, Mallucci C. Does pre-resection endoscopic third ventriculostomy prevent the need for post-resection CSF diversion after pediatric posterior fossa tumor excision? A historical cohort study and review of the literature. J Neurosurg Pediatr 2020; 25:615-624. [PMID: 32084638 DOI: 10.3171/2019.12.peds19539] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/15/2019] [Accepted: 12/16/2019] [Indexed: 11/06/2022]
Abstract
OBJECTIVE Children with posterior fossa tumors (PFTs) may present with hydrocephalus. Persistent (or new) hydrocephalus is common after PFT resection. Endoscopic third ventriculostomy (ETV) is sometimes performed prior to resection to 1) temporize hydrocephalus prior to resection and 2) prophylactically treat post-resection hydrocephalus. The objective of this study was to establish, in a historical cohort study of pediatric patients who underwent primary craniotomy for PFT resection, whether or not pre-resection ETV prevents the need for post-resection CSF diversion to manage hydrocephalus. METHODS The authors interrogated their prospectively maintained surgical neuro-oncology database to find all primary PFT resections from a single tertiary pediatric neurosurgery unit. These data were reviewed and supplemented with data from case notes and radiological review. The modified Canadian Preoperative Prediction Rule for Hydrocephalus (mCPPRH) score was retrospectively calculated for all patients. The primary outcome was the need for any form of postoperative CSF diversion within 6 months of PFT resection (including ventriculoperitoneal shunting, ETV, external ventricular drainage [EVD], and lumbar drainage [LD]). This was considered an ETV failure in the ETV group. The secondary outcomes were time to CSF diversion, shunt dependence at 6 months, and complications of ETV. Statistical analysis was done in RStudio, with significance defined as p < 0.05. RESULTS A total of 95 patients were included in the study. There were 28 patients in the ETV group and 67 in the non-ETV group. Patients in the ETV group were younger (median age 5 vs 7 years, p = 0.04) and had more severe preoperative hydrocephalus (mean frontal-occipital horn ratio 0.45 vs 0.41 in the non-ETV group, p = 0.003) and higher mCPPRH scores (mean 4.42 vs 2.66, p < 0.001). The groups were similar in terms of sex and tumor histology. The overall rate of post-resection CSF diversion of any kind (shunt, repeat ETV, LD, or EVD) in the entire cohort was 25.26%. Post-resection CSF diversion was needed in 32% of patients in the ETV group and in 22% of the patients in the non-ETV group (p > 0.05). Shunt dependence at 6 months was seen in 21% of the ETV group and 16% of the non-ETV group (p > 0.05). The median time to ETV failure was 9 days. ETV failure correlated with patients with ependymoma (p = 0.02). Children who had ETV failure had higher mCPPRH scores than the ETV success group (5.67 vs 3.84, p = 0.04). CONCLUSIONS Pre-resection ETV did not reliably prevent the need for post-resection CSF diversion. ETV was more likely to fail in children with ependymoma and those with higher mCPPRH scores. Based on the findings of this study, the authors will change the practice at their institution; pre-resection ETV will now be performed based on a newly defined protocol.
Collapse
Affiliation(s)
- Harishchandra Lalgudi Srinivasan
- 1Department of Neurosurgery, Alder Hey NHS Foundation Trust, Liverpool
- 3Department of Paediatric Neurosurgery, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel
| | - Mitchell T Foster
- 2Department of Neurosurgery, Walton Centre NHS Foundation Trust, Liverpool, United Kingdom; and
| | | | - Dawn Hennigan
- 1Department of Neurosurgery, Alder Hey NHS Foundation Trust, Liverpool
| | | | - Conor Mallucci
- 1Department of Neurosurgery, Alder Hey NHS Foundation Trust, Liverpool
| |
Collapse
|
37
|
Aljaaf AJ, Van Tonder L, Mallucci C, Al-Jumeily D, Hussain A, Alloghani M. Patients Attitude to Technology : A Way to Improve Hydrocephalus Management and Follow up Using Smartphone Intelligent Application. J Med Syst 2019; 43:295. [PMID: 31342275 DOI: 10.1007/s10916-019-1420-4] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2019] [Accepted: 07/10/2019] [Indexed: 11/30/2022]
Abstract
Smartphone applications ("apps") have become ubiquitous with the advent of smartphones and tablets in recent years. Increasingly the utility of these apps is being explored in healthcare delivery. Hydrocephalus is a condition that is usually followed by a neurosurgeon for the patient's life. We explore patient acceptability of a mobile app as an adjunct to outpatient follow-up of patients with hydrocephalus. A questionnaire was circulated amongst patients with hydrocephalus (adults and children). Patients were asked questions about their hydrocephalus; expectations for outpatient follow up, whether they have smartphone/tablet/internet access and whether they would be interested in a mobile app for their long term hydrocephalus follow up. 191 patients completed questionnaires, 98 respondents were adults (mean age 46.1) and 93 were children less than 18 years old (mean age 8). Overall 36.1% of patients did not know the cause of their hydrocephalus. 96.7% have a shunt. 76.5% of adults and 80.6% of children had 1-4 shunt surgeries, 14.3% of adults and 11.8% of children had 5-9 shunt surgeries, 3.1% of adults and 5.4% of children had 10-14 shunt surgeries. 71.7% of patients expect to be followed-up routinely in clinic for life. All children had smartphones or tablets, compared to 86.7% of adults. Children were more interested in a hydrocephalus app, 84.9% saying yes, compared to 71.4% of adults. Adults who were not interested in the app did not have a smartphone or tablet. Hydrocephalus management is a lifelong task and innovations in technology for engaging patients in its management are vital. The majority of patients are interested in mobile apps for outpatient management of hydrocephalus. We will follow this up with a feasibility study of a custom designed hydrocephalus app.
Collapse
Affiliation(s)
- Ahmed J Aljaaf
- Centre of Computer, University of Anbar, Ramadi, Iraq. .,Faculty of Engineering, Technology, LJMU, Liverpool, UK.
| | | | | | | | - Abir Hussain
- Faculty of Engineering, Technology, LJMU, Liverpool, UK
| | - Mohamed Alloghani
- Abu Dhabi Health Services Company (SEHA), Abu Dhabi, United Arab Emirates
| |
Collapse
|
38
|
Foster MT, Grayston R, Hennigan D, Harishchandra LS, Tonder LV, Millward CP, Pettorini B, Sinha A, Parks C, Burn S, Pizer B, Mallucci C. FP2-3 Ten years of paediatric neuro-oncology surgery: quantifying and predicting complications after surgery for intracranial tumour excision. J Neurol Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.81] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesTo measure complications of paediatric neurooncology surgery using the Clavien Dindo grading scale, and identify predictors of surgical morbidity.DesignRetrospective review of prospectively collected data.SubjectsAll paediatric patients treated with craniotomy for excision of intracranial tumour between 2008 and 2017 in a single tertiary paediatric neurosurgery centre.MethodsDemographics, surgical details and perioperative complications were prospectively recorded between 0 and 30 days post operatively. These were retrospectively graded using the CD scale. Data analysis was done in R using logistic regression. Significance was defined as p<0.05ResultsBetween 3/1/2008 and 21/12/2017 there were 322 operations, on 254 patients (142 Male). Median age at surgery was 9 years (IQR 4–13 years). 48% were without complication on the CD scale. Maximum CD grade complication for each procedure was 1 in 11%, 2 in 19%, 3A in 2%, 3B in 14%, and 4 in 0.6% of operations. 30 day mortality was 0.9%. CD grade of 3B or over was associated with infratentorial tumours (OR 2.24; CI 1.10–4.68; p=0.004) and WHO grade III tumours (OR 4.12; CI 1.56–10.86; p=0.028).ConclusionsComplications in paediatric neurooncology surgery are common overall, but our results are favourable in comparison to the literature. The CD scale has limitations in neurosurgery but gives insight into the health economic impact of complications. Infratentorial tumours, and WHO grade III tumours were associated with increased morbidity.
Collapse
|
39
|
Millward CP, Tonder LV, Foster M, Williams D, Griffiths M, Kneen R, Sinha A, Mallucci C. P96 Screening for cerebrovascular pathology on the basis of positive family history in the paediatric population. J Neurol Neurosurg Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.153] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesNeurovascular disorders are uncommon, complex conditions in children. We reviewed the screening practice and outcome of children referred to the neurovascular service on the basis of positive family history.DesignRetrospective review of prospectively maintained database.SubjectsChildren referred to the neurovascular service on the basis of family history, for screening at our hospital.MethodsWe retrospectively examined our database between July 2008 and April 2018 for the reasons for referral, family history, investigations performed, and the outcome of the screening process.Results44 children were reviewed (23 male, median age 10). Thirty-one children had an MRI/MRA brain. One child subsequently had uncomplicated digital subtraction angiography. Thirty children were referred due to a family history of subarachnoid haemorrhage, of which 17 had a single first-degree relative, and two had two first-degree relatives. Nine children were referred with a family history of arteriovenous malformation, (2 were associated with hereditary haemorrhagic telangiectasia). Five children were discussed due to a family history of non-specific haemorrhagic stroke. Seven children had a history of headache, (4 were prescribed Pizotifen for migraine). No neurovascular pathology was detected following screening within our cohort.ConclusionsA consensus screening policy does not exist but is required both to guide clinical practice and to assuage parental or patient concerns. We will survey UK paediatric centres to commence this process.
Collapse
|
40
|
Tonder LV, Foster M, Hennigan D, Kneen R, Iyer A, Parks C, Burn S, Mallucci C. TP1-10 Non tumour brain biopsies in alder hey paediatric neurosurgery. J Neurol Neurosurg Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.39] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesTo review the utility of non-tumour brain biopsies in Alder Hey Children’s NHS Foundation Trust Paediatric Neurosurgery Department.MethodsOperative records were searched for ‘biopsy’. Case notes were reviewed for referral source, histology, surgical complication and outcome. Tumour, epilepsy and non-brain biopsy cases were excluded.Results83 ‘biopsy’ cases were identified between 2008 and 2017. 31 tumour, 5 epilepsy, 2 infections and 28 non brain/other biopsies were excluded. 17 brain biopsies for non-tumour causes were seen. 15 patients were referred by neurology, 2 by rheumatology. 14 underwent a craniotomy/mini-craniotomy, 3 had burrholes.4 biopsies were non diagnostic, 2 were abnormal but inconclusive for diagnosis. Diagnoses included: 3 demyelinating lesions, 2 normal brain tissue, 1 neurosarcoidosis, 1 autoimmune encephalitis, 1 definite Rasmussen’s Encephalitis, 1 possible Rasmussen’s Encephalitis, 1 systemic lupus erythematosus associated CNS vasculitis, 1 inflammatory infiltrate (secondary to hydrocephalus/ventriculitis), 1 patient developed a late wound infection. No other surgical morbidities/mortalities were recorded. 11 of these cases had a change in management or the treating team were reassured due to the result of the biopsy (i.e. were able to start immunomodulatory drugs in the absence of infection).Conclusions65% of brain biopsies were diagnostic. 71% of biopsies either changed management or reassured the treating team about a line of management. The procedure is low risk with 0.06% morbidity and 0% mortality.
Collapse
|
41
|
Millward CP, Foster M, Tonder LV, Williams D, Pizer B, Pettorini B, Parks C, Mallucci C. P98 A decade of primary tumours of the spine in the paediatric population. J Neurol Psychiatry 2019. [DOI: 10.1136/jnnp-2019-abn.155] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022]
Abstract
ObjectivesPrimary spinal tumours in children are rare and poorly understood; we review 10 years of surgical experience.DesignRetrospective review of prospectively maintained database.SubjectsChildren receiving surgical management of primary spinal tumours in a single, tertiary paediatric neurosurgery centre.MethodsOperations for primary spinal tumours were abstracted from our prospectively maintained surgical database and supplemented with data from case notes, operative records, and imaging studies.ResultsBetween 2008 and 2017, 37 procedures were performed on 29 patients (19 male; Median age 7.5 years, IQR 2–11.25). 28 had their primary procedure in our unit: 21 excisions, and 7 biopsies (of which 5 proceeded to further surgery). Tumours were classified as extradural (10), intradural extramedullary (3), intradural intramedullary (11) or bony (4). Tumours were found at the following levels: Cervical (8; 29%), Cervicothoracic (2; 7.1%), Thoracic (10; 36%), Thoracolumbar (3; 11%), Lumbar (2; 7.1%), Lumbosacral (2; 7.1%) and Sacral (1; 3.6%). Histology comprised: Pilocytic Astrocytoma (6), Other Astrocytoma (4), Schwannoma (3), Ewing Sarcoma (2), Langerhans cell histiocytosis (2), Lymphoma (2), Neurofibroma (2), and others (7) including one Myxopapillary Ependymoma.ConclusionsThe rarity and heterogeneity of paediatric spinal tumours makes treatment challenging. We propose a national online registry including a tissue bank, and invite collaboration with other units.
Collapse
|
42
|
van Tonder L, Burn S, Iyer A, Blair J, Didi M, Carter M, Martland T, Mallucci C, Chawira A. Open resection of hypothalamic hamartomas for intractable epilepsy revisited, using intraoperative MRI. Childs Nerv Syst 2018; 34:1663-1673. [PMID: 29752488 DOI: 10.1007/s00381-018-3786-x] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/14/2017] [Accepted: 03/27/2018] [Indexed: 12/14/2022]
Abstract
INTRODUCTION Hypothalamic hamartomas (HHs) are rare non-neoplastic lesions which cause drug-resistant epilepsy with associated behavioural, psychiatric and endocrine issues. With the development of new minimally invasive techniques for the treatment of HH, there is a need to reappraise the effectiveness and safety of each approach. We review the outcomes of HH patients treated surgically, utilizing intraoperative magnetic resonance imaging (IOMRI), by a team of Alder Hey NHS Foundation Trust tumour and epilepsy neurosurgeons since 2011. METHODS Patient records of all HH cases operated on since 2011 were reviewed to confirm history of presentation and clinical outcomes. RESULTS Ten patients have undergone surgery for HH under the dual care of Alder Hey tumour and epilepsy neurosurgeons during this period. Eight cases had a midline transcallosal, interforniceal approach with the remaining 2 having a transcallosal, transforaminal approach. All patients had an IOMRI scan, with 40% needing further tumour resection post-IOMRI. Forty percent had a total resection, 3 patients had near-total resection and 3 patients had subtotal resection (~ 30% tumour residual on post-operative MRI). No new neurological complications developed post-operatively. Hypothalamic axis derangements were seen in 3 cases, including 1 diabetes insipidus with hypocortisolaemia, 1 hypodipsia and 1 transient hyperphagia. Eighty percent are seizure free; the remaining two patients have had significant improvements in seizure frequency. CONCLUSIONS IOMR was used to tailor the ideal tumour resection volume safely based on anatomy of the lesion, which combined with the open transcallosal, interforniceal route performed by surgeons experienced in the approach resulted in excellent, safe and effective seizure control.
Collapse
Affiliation(s)
- Libby van Tonder
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK.
| | - Sasha Burn
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Anand Iyer
- Department of Paediatric Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Jo Blair
- Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Mohammed Didi
- Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Michael Carter
- Department of Neurosurgery, Bristol Royal Hospital for Children, Bristol, BS2 8BJ, UK
| | - Timothy Martland
- Department of Paediatric Neurology, Royal Manchester Children's Hospital (RMCH), Manchester, M13 9WL, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Athanasius Chawira
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| |
Collapse
|
43
|
van Tonder L, Burn S, Iyer A, Blair J, Didi M, Carter M, Martland T, Mallucci C, Chawira A. Correction to: Open resection of hypothalamic hamartomas for intractable epilepsy revisited, using intraoperative MRI. Childs Nerv Syst 2018; 34:1675. [PMID: 30027455 DOI: 10.1007/s00381-018-3900-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Abstract
The authors apologize to have sent a final manuscript draft omitting "Athanasius Chawira" from the list of authors. The correct list of authors is given in this article.The original article has been corrected.
Collapse
Affiliation(s)
- Libby van Tonder
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK.
| | - Sasha Burn
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Anand Iyer
- Department of Paediatric Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Jo Blair
- Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Mohammed Didi
- Department of Endocrinology, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Michael Carter
- Department of Neurosurgery, Bristol Royal Hospital for Children, Bristol, BS2 8BJ, UK
| | - Timothy Martland
- Department of Paediatric Neurology, Royal Manchester Children's Hospital (RMCH), Manchester, M13 9WL, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| | - Athanasius Chawira
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, L12 2AP, UK
| |
Collapse
|
44
|
Hartley H, Pizer B, Lane S, Sneade C, Williams R, Mallucci C, Bunn L, Kumar R. Incidence and prognostic factors of ataxia in children with posterior fossa tumors. Neurooncol Pract 2018; 6:185-193. [PMID: 31386000 DOI: 10.1093/nop/npy033] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Background There is minimal literature specific to motor outcomes in children with posterior fossa tumors (PFTs) despite ataxia being a significant problem in this group. This study aims to report children's physical outcomes following management of PFT and determine which factors affect severity of ataxia and functional limitations. Methods Forty-two children aged between 5 and 17 and between 1 and 4 years following surgery for PFT were assessed using the Scale for the Assessment and Rating of Ataxia (SARA), the Brief Ataxia Rating Scale (BARS), and the mobility Pediatric Evaluation of Disability Inventory (PEDI) subscale to determine prevalence and severity of ataxia and a measure of physical function. Analysis was undertaken comparing impact of tumor location, tumor histology, adjuvant treatment, age at diagnosis, presence of preoperative ataxia, and presence of cerebellar mutism syndrome (CMS) on ataxia and physical function scores. Results Seventy-one percent of children demonstrated a SARA and BARS score greater than 2. A total of 48% of children had a PEDI-m score greater than 90. There was no correlation between age at diagnosis or preoperative ataxia and assessment scores. There was a significant difference in SARA/BARS and PEDI-mobility scores depending on tumor histology, tumor location, and presence of CMS. Conclusions A high proportion of children (>1 year) following surgery for PFT continue to present with ataxia. Higher ataxia and lower physical function scores were demonstrated in children with medulloblastoma and midline tumors and those diagnosed with CMS. The high prevalence of ataxia demonstrates the need for further research regarding rehabilitation management in this population.
Collapse
Affiliation(s)
- Helen Hartley
- Physiotherapy Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Barry Pizer
- Oncology Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Steven Lane
- Department of Biostatistics, University of Liverpool, UK
| | - Christine Sneade
- Physiotherapy Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Rebecca Williams
- Physiotherapy Department, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| | - Lisa Bunn
- School of Health Professions, University of Plymouth, UK
| | - Ram Kumar
- Department of Neurology, Alder Hey Children's NHS Foundation Trust, Liverpool, UK
| |
Collapse
|
45
|
Tejada S, Avula S, Pettorini B, Mallucci C. NSRG-12. EXPERIENCE WITH THE INTRAOPERATIVE MAGNETIC RESONANCE IN PEDIATRIC BRAIN TUMOR SURGERY. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.534] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
- Sonia Tejada
- Clínica Universidad de Navarra, Pamplona, Navarra, Spain
| | | | | | | |
Collapse
|
46
|
Gan HW, Aquilina K, Morillon P, Albanese A, Barkas K, Chandler C, Chang YC, Daousi C, Drimtzias E, Farndon S, Jacques T, Korbonits M, Kuczynski A, Limond J, Robinson L, Simmons I, Thomas N, Thomas S, Thorpe N, Vargha-Khadem F, Warren D, Zebian B, Mallucci C, Gamble A, Wilne S, Harrison B, Spoudeas H. CRAN-08. NATIONAL UK GUIDELINES FOR THE INVESTIGATION, TREATMENT AND LONG-TERM FOLLOW-UP OF PAEDIATRIC CRANIOPHARYNGIOMA. Neuro Oncol 2018. [DOI: 10.1093/neuonc/noy059.045] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- Hoong-Wei Gan
- University College London Great Ormond Street Institute of Child Health, London, UK
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | - Kristian Aquilina
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | | | - Assunta Albanese
- St. George’s University Hospitals NHS Foundation Trust, London, UK
| | | | - Chris Chandler
- King’s College Hospital NHS Foundation Trust, London, UK
| | - Yen-Ching Chang
- University College London Hospitals NHS Foundation Trust, London, UK
| | | | | | - Sarah Farndon
- East and North Hertfordshire NHS Trust, Stevenage, UK
| | - Tom Jacques
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | | | - Adam Kuczynski
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | | | - Louise Robinson
- Royal Manchester Children’s Hospital, Central Manchester University Hospitals NHS Foundation Trust, Manchester, UK
| | - Ian Simmons
- Leeds Teaching Hospitals NHS Trust, Leeds, UK
| | - Nick Thomas
- King’s College Hospital NHS Foundation Trust, London, UK
| | - Sophie Thomas
- Nottingham Children’s Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Nicola Thorpe
- The Clatterbridge Cancer Centre NHS Foundation Trust, Birkenhead, UK
| | - Faraneh Vargha-Khadem
- University College London Great Ormond Street Institute of Child Health, London, UK
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| | | | - Bassel Zebian
- King’s College Hospital NHS Foundation Trust, London, UK
| | - Conor Mallucci
- Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
| | - Ashley Gamble
- UK Children’s Cancer and Leukaemia Group, Leicester, UK
| | - Sophie Wilne
- Nottingham Children’s Hospital, Nottingham University Hospitals NHS Trust, Nottingham, UK
| | - Barney Harrison
- Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK
| | - Helen Spoudeas
- Great Ormond Street Hospital for Children NHS Foundation Trust, London, UK
| |
Collapse
|
47
|
Kilday JP, Caldarelli M, Massimi L, Chen RHH, Lee YY, Liang ML, Parkes J, Naiker T, van Veelen ML, Michiels E, Mallucci C, Pettorini B, Meijer L, Dorfer C, Czech T, Diezi M, Schouten-van Meeteren AYN, Holm S, Gustavsson B, Benesch M, Müller HL, Hoffmann A, Rutkowski S, Flitsch J, Escherich G, Grotzer M, Spoudeas HA, Azquikina K, Capra M, Jiménez-Guerra R, MacDonald P, Johnston DL, Dvir R, Constantini S, Kuo MF, Yang SH, Bartels U. Intracystic interferon-alpha in pediatric craniopharyngioma patients: an international multicenter assessment on behalf of SIOPE and ISPN. Neuro Oncol 2018; 19:1398-1407. [PMID: 28499018 DOI: 10.1093/neuonc/nox056] [Citation(s) in RCA: 51] [Impact Index Per Article: 8.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Abstract
Background Craniopharyngiomas are frequent hypothalamo-pituitary tumors in children, presenting predominantly as cystic lesions. Morbidity from conventional treatment has focused attention on intracystic drug delivery, hypothesized to cause fewer clinical consequences. However, the efficacy of intracystic therapy remains unclear. We report the retrospective experiences of several global centers using intracystic interferon-alpha. Methods European Société Internationale d'Oncologie Pédiatrique and International Society for Pediatric Neurosurgery centers were contacted to submit a datasheet capturing pediatric patients with cystic craniopharyngiomas who had received intracystic interferon-alpha. Patient demographics, administration schedules, adverse events, and outcomes were obtained. Progression was clinical or radiological (cyst reaccumulation, novel cysts, or solid growth). Results Fifty-six children (median age, 6.3 y) from 21 international centers were identified. Median follow-up from diagnosis was 5.1 years (0.3-17.7 y). Lesions were cystic (n = 22; 39%) or cystic/solid (n = 34; 61%). Previous progression was treated in 43 (77%) patients before interferon use. In such cases, further progression was delayed by intracystic interferon compared with the preceding therapy for cystic lesions (P = 0.0005). Few significant attributable side effects were reported. Progression post interferon occurred in 42 patients (median 14 mo; 0-8 y), while the estimated median time to definitive therapy post interferon was 5.8 (1.8-9.7) years. Conclusions Intracystic interferon-alpha can delay disease progression and potentially offer a protracted time to definitive surgery or radiotherapy in pediatric cystic craniopharyngioma, yet demonstrates a favorable toxicity profile compared with other therapeutic modalities-important factors for this developing age group. A prospective, randomized international clinical trial assessment is warranted.
Collapse
Affiliation(s)
- John-Paul Kilday
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Massimo Caldarelli
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Luca Massimi
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Robert Hsin-Hung Chen
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Yi Yen Lee
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Muh-Lii Liang
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Jeanette Parkes
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Thuran Naiker
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Marie-Lise van Veelen
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Erna Michiels
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Conor Mallucci
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Benedetta Pettorini
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Lisethe Meijer
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Christian Dorfer
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Thomas Czech
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Manuel Diezi
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Antoinette Y N Schouten-van Meeteren
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Stefan Holm
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Bengt Gustavsson
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Martin Benesch
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Hermann L Müller
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Anika Hoffmann
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Stefan Rutkowski
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Joerg Flitsch
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Gabriele Escherich
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Michael Grotzer
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Helen A Spoudeas
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Kristian Azquikina
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Michael Capra
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Rolando Jiménez-Guerra
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Patrick MacDonald
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Donna L Johnston
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Rina Dvir
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Shlomi Constantini
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Meng-Fai Kuo
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Shih-Hung Yang
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| | - Ute Bartels
- Children's Brain Tumour Research Network (CBTRN), Royal Manchester Children's Hospital, Oxford Road, Manchester, England, UK; The Centre for Paediatric, Teenage and Young Adult Cancer, Institute of Cancer Sciences, The University of Manchester, England, UK; Department of Pediatric Neurosurgery, A Gemelli Hospital, Rome, Italy; Division of Pediatric Neurosurgery, Neurological Institute, Taipei Veterans General Hospital, Taipei, Taiwan; Groote Schuur Hospital, University of Cape Town, South Africa; Sophia Children's Hospital, Erasmus MC, Rotterdam, Netherlands; Department of Neurosurgery, Alder Hey Children's Hospital NHS Foundation Trust, Liverpool, England, UK ; Beatrix Childrens' Hospital, University MC, Groningen, Netherlands; Department of Neurosurgery, Medical University of Vienna, Vienna, Austria; Pediatric Haemato-Oncology Unit, University Hospital Lausanne, Switzerland; Pediatric Oncology Department, Emma Children's Hospital of the Academic Medical Center, Amsterdam, Netherlands; Department of Pediatric Neurosurgery, Karolinska University Hospital, Stockholm, Sweden; Division of Pediatric Hematology and Oncology, Department of Pediatrics and Adolescent Medicine, Medical University of Graz, Graz, Austria; Department of Pediatrics, Klinikum Oldenburg AöR, Medical Campus University Oldenburg, Oldenburg, Germany; Departments of Neurosurgery and Oncology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany; Department of Neurosurgery, University Children's Hospital Zurich, Switzerland; Departments of Paediatric Neuroendocrinology and Neurosurgery, Great Ormond Street Hospital, London, England, UK; Department of Paediatrics, Our Lady's Children's Hospital, Crumlin, Ireland; Department of Pediatric Neurosurgery, Hospital Angeles Mexico, Mexico City,Mexico; Department of Neurosurgery, Winnipeg Children's Hospital, Canada; Department of Paediatrics, Children's Hospital of Eastern Ontario, Ottawa, Canada; Department of Neurosurgery, Tel-Aviv Sourasky Medical Center, Israel; Department of Neurosurgery, National Taiwan University Hospital, Taiwan; Department of Paediatric Oncology, The Hospital for Sick Children, Toronto, Canada
| |
Collapse
|
48
|
Waqar M, Ellenbogen JR, Mallucci C. Endoscopic third ventriculostomy for shunt malfunction in children: A review. J Clin Neurosci 2018; 51:6-11. [DOI: 10.1016/j.jocn.2018.02.012] [Citation(s) in RCA: 18] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/24/2017] [Revised: 01/10/2018] [Accepted: 02/04/2018] [Indexed: 11/26/2022]
|
49
|
Tejada S, Avula S, Pettorini B, Henningan D, Abernethy L, Mallucci C. The impact of intraoperative magnetic resonance in routine pediatric neurosurgical practice-a 6-year appraisal. Childs Nerv Syst 2018; 34:617-626. [PMID: 29460065 DOI: 10.1007/s00381-018-3751-8] [Citation(s) in RCA: 19] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/02/2017] [Accepted: 02/04/2018] [Indexed: 10/18/2022]
Abstract
BACKGROUND The intraoperative magnetic resonance scanner (ioMR) was introduced in our unit in 2009, and has been used routinely since then. OBJECTIVE This study aims to describe indications, radiological features, and clinical outcomes of the patients operated on with ioMRI and analyze our experience. METHODS A retrospective analysis of a prospective surgical database has been performed, including surgical procedure, intent, radiological reports, need for second-look surgery, and complications, supplemented by further review of the clinical notes and the scans. RESULTS From 2009 to 2015, 255 surgical procedures with ioMR were performed: 175 were craniotomies for tumor excision, 65 were epilepsy related, and 15 were biopsies or cyst drainages. The mean age was 9.4 years. One ioMR was performed in 79.5% patients; the mean duration of the MR was 41 min. In 172 cases (67.4%), no actions followed the ioMR. When the aim of the surgery was debulking of the tumor, the percentage of patients in which the ioMR was followed by resection was higher than when complete resection was the aim (56 vs 27.5%). The complication rate was not increased when compared with our previous results (infection 1%, neurological deficits 12%). CONCLUSION This is the largest published series of ioMRI-aided pediatric neurosurgery to date. We have demonstrated that it can be used safely and routinely in pediatric neurosurgical procedures at any age, assisting the surgeon in achieving the best extent of resection and aiding in intra-operative decision-making for tumor- and non-tumor-related intracranial pathology.
Collapse
Affiliation(s)
- Sonia Tejada
- Department of Neurosurgery, Clínica Universidad de Navarra, Calle Pio XII, 36, 31008, Pamplona, Spain.
| | - Shivaram Avula
- Department of Radiology, Alder Hey Children's NHS Foundation, Liverpool, UK
| | - Benedetta Pettorini
- Department of Neurosurgery, Alder Hey Children's NHS Foundation, Liverpool, UK
| | - Dawn Henningan
- Department of Neurosurgery, Alder Hey Children's NHS Foundation, Liverpool, UK
| | - Laurence Abernethy
- Department of Radiology, Alder Hey Children's NHS Foundation, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation, Liverpool, UK
| |
Collapse
|
50
|
Stagno V, Mallucci C, Avula S, Pizer B. The use of neo adjuvant single-agent vinblastine for tumour shrinkage in a highly vascular paediatric low-grade glioma. Br J Neurosurg 2018; 34:207-209. [PMID: 29405073 DOI: 10.1080/02688697.2018.1427212] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
Vinblastine has shown activity as second line treatment in Low Grade Glioma (LGG) in children as well as anti-angiogenic activity in vitro.A 5 year old girl presented with 6 week history of headaches. MRI demonstrated a right temporo-parietal mass with abnormal pathological vasculature including aneurysmal vessels. Biopsy showed a pilocytic astrocytoma. Due to increased risk from surgery, first line treatment with vinblastine was given.Over 10 months, progressive reduction of tumour vascularity was demonstrated. The tumour was then surgically removed after 14 months of therapy.To our knowledge, this is the first report in which vinblastine has been successfully used in LGG to obtain tumour shrinkage prior to total tumor resection in a high vascularized LGG.
Collapse
Affiliation(s)
- Vita Stagno
- Department of Neurosurgery, Alder Hey Children's NHS Foundation trust, Liverpool, UK
| | - Conor Mallucci
- Department of Neurosurgery, Alder Hey Children's NHS Foundation trust, Liverpool, UK
| | - Shivaram Avula
- Department of Radiology, Alder Hey Children's NHS Foundation trust, Liverpool, UK
| | - Barry Pizer
- Department of Oncology, Alder Hey Children's NHS Foundation trust, Liverpool, UK
| |
Collapse
|